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Abstract
Muscles give our bodies the ability to move by stretching and contracting. While
contraction is accomplished by the well-known actin-myosin interaction, not much is known
about stretch. Two integral muscle proteins involved in stretch are titin and obscurin; both are
long rope-like protein molecules that seem to act as molecular springs. Mutations in these two
proteins can lead to diseases such as hypertrophic cardiomyopathy and muscular dystrophy, as
well as a variety of cancers. In an effort to understand muscle stretch and signaling on a more
fundamental level, here we present the high resolution structure of obscurin Ig59, a domain
involved in titin/obscurin binding. We also describe how unbound titin moves when stretched.
Last, we describe ongoing work in elucidating the high-resolution structures and
activation/inhibition mechanisms of obscurin domains Rho-GEF, Rho-GEF-PH, kinase I (KI),
and kinase II (KII).
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Preface/Introduction
Muscles, Muscle Proteins, and Structure of the Sarcomere
Muscles give our bodies the ability to move by stretching and contracting. Without
them, we would not be able to walk, stand up, or perform any of the motions do throughout our
daily lives. Striated muscles, the ones connected to our skeleton, allow for virtually all
voluntary movement of our body. As the name implies, this kind of muscle is made up of a
series of different bands that are visible in the light microscope, termed the A-band and the Iband. One A-band and half of the neighboring I-band form the sarcomere, the smallest
contracting segment of muscle. Hundreds of sarcomeres lie end-to-end, making up the syncytial
cell type called the myofibril. These cell types are the largest in the human body; the longest
can be more than a foot long. Many myofibrils are bundled together into a single fascicle,
which in turn is bundled into a muscle (Fig. 1).

Figure 1. Schematic representation of the muscle, showing its breakdown into fascicles, fibers, and
sarcomeres (adapted from John Wiley & Sons, Inc., 2013).

Figure 2. Steps of muscle contraction showing the process of
calcium release and binding to troponin, conformation changes of
troponin and tropomyosin, hydrolysis of ATP, power stroke,
binding of ATP to myosin, and release of bound calcium from
troponin (taken from https://mykindofscience.com/2015/01/20/myawe-of-the-human-body-muscle-movement-2/).
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When a muscle
contracts, myosin thick
filaments slide across F-actin
thin filaments in an ATP- and
calcium-requiring reaction,
resulting in a shortening of
the sarcomere. This process,
termed the sliding filament
model, involves a number of
simple steps to produce
contraction. When the brain
generates an electrical signal
in the form of an action
potential, it courses along
through the somatic nervous
system to the axon of a motor
neuron, which is connected to
a skeletal muscle cell.
Acetylcholine is released by
neurotransmitters within the

synaptic cleft, which binds to membrane proteins in the outer layer of the muscle cell,
depolarizing it. This depolarization allows the action potential to travel into the cell and activate
Ryanodine receptor-dependent calcium channels within the sarcoplasmic reticulum. Calcium
ions flow into the muscle cell as a result and bind to troponin in the thin filament region of the
muscle cell. The calcium binding induces a conformation change in the troponin protein, which
in turn alters the tropomyosin-actin interaction. The new conformation of tropomyosin exposes
the myosin binding sites on actin (the thin filament). Once the myosin binding sites are
exposed, head structures on the myosin molecules hydrolyze bound ATP and reorient to bind to
actin. Finally, release of ADP and Pi from the myosin head generates a power stroke (Fig. 2,
steps 1 and 2) that brings adjacent Z lines closer to each other, shortening the length of the
sarcomere and contracting the cell (Fig. 2, step 3. The cell returns to a relaxed state when ATP
binds to myosin and the calcium ion bound to troponin is released (Fig. 2, step 4).
In order for these ultrastructural filaments to perform their jobs and contribute to overall
muscle contraction, the sarcomere must be exquisitely well ordered. If the thick filaments did
not interdigitate the thin filaments, there would be no contraction. Similarly, if the thick and
thin filaments did not overlap, there would be no power stroke. The almost paracrystalline-like
array of contractile apparatus is accomplished through the cytoskeleton; particularly, through
the involvement of the giant cytoskeletal proteins titin, nebulin, and obscurin.
Titin, the longest known polypeptide at 3-5 MDa, has its N- and C-termini anchored in
the Z-disc and M-line, respectively. Titin generates passive elasticity of muscles by acting as a
force sensor and regulates the length of the thick filament of the sarcomere (Trinick, 1992; Hsin
et al., 2011; Fig. 3, red). Throughout its considerable length, it binds to and anchors many
proteins to the surrounding cytoskeleton and acts as a molecular spring, regulating amount of
stretch in the sarcomere. Nebulin (600-800 kDa) stabilizes the thin filament and may also have
some function in regulating the length of the thin filament, directing actin/myosin interactions,
and myofibrillar force generation (Trinick, 1992; Chu et al., 2016; KontrogianniKonstantopoulos et al., 2009). Last, obscurin connects the sarcomere to the surrounding
sarcoplasmic reticulum via its interaction with titin (Fig. 3) and aids in assembly of myofibrils
and the sarcoplasmic reticulum (Meyer and Wright, 2003; Lee et al., 2010; Bang et al., 2001;
Young et al., 2001; Armani et al., 2006; Kontrogianni-Konstantopoulos and Bloch, 2009).
Obscurin and titin are the focus of
my research.
Due to their large size and
complexity, titin and obscurin have
been difficult to study using
traditional molecular biology or
biochemistry techniques. However,
both are highly modular in overall
architecture. Titin has
approximately 300 independently
folded domains while obscurin has
at least 70, though the exact number
depends on the isoform; each
domain of titin consists of
approximately 100 amino acids
(Meyer and Wright, 2013). The
Figure 3. Schematic representation of the sarcomere. Titin (red)
most
common folds are the
anchors the M-line and Z-disc and regulates the length of the
immunoglobulin
(Ig) and
sarcomere. Obscurin (blue) tethers titin to the sarcoplasmic
reticulum. Nebulin (green) regulates the length of the thin
Fibronectin typeIII-like (FnIII-like)
filaments (actin, under the green). Myosin heads (grey) slide
domains, which both fold into
across the thin filaments as a muscle contracts (taken from
variations of a β-sandwich fold.
Meyer and Wright, 2013).
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(Meyer and Wright, 2003; Fig. 4). Rather than trying to discern structure/function relationships
of the entire obscurin or titin molecule, we (and others) have instead found it more useful to
focus on solving the high-resolution structure of individual domains. In other words, we choose
to describe the obscurin and titin structure/function relationship from a bottom-up approach,
from domains to whole molecules. To this end, I will begin with an overview of titin and
obscurin, their associated diseases and then move onto a more in-depth discussion of obscurin.
Titin
is found
mostly in
skeletal and
cardiac
muscle tissue
and spans the
sarcomere
from the Zdisk to the
M-band
Figure 4. Cartoon representation and schematic of A.) an Ig domain and B.) a FnIII(Bang et al.,
like domain. The cartoon representations are colored from N-terminus (blue) to C2001;
terminus (red) (adapted from Meyer and Wright).
Granzier and
Wang, 1993;
Linke, 1994; Kontrogianni-Konstantopoulos et al., 2009). In the body, titin regulates the length
of the sarcomere and helps restore the pre-contraction length, protecting the sarcomere from
injury caused by overstretching (Lee et al., 2010). Titin’s ability to both stretch and recoil is
fundamental in preventing muscle overstretching, and helps myocytes return to their original
length (Gautel, 2011; Improta et al. 1998). In this capacity, titin acts as a mechanosensor
(Kontrogianni-Konstantopoulos et al., 2009; Linke 2008; Meyer and Wright, 2003).

Figure 5. Schematic representation of the structure and binding partners of titin A-M (the portion of titin
spanning from the A-line to the M-line). Note that the key provided lists the domain types as well as the
meaning of the colors and shapes used in the schematic (adapted from Kontrogianni-Konstantopoulos,
2009).

A decidedly important player in muscle contraction, titin has a multitude of binding
partners, one of which is obscurin (Fig. 6). Obscurin (~720-900 kDa) is made up of mostly Ig
domains and binds to titin in the Z-disk region of the sarcomere (Young et al., 2001; Bang et
al., 2001) (Fig. 5&6). With titin bound at its N-terminus and small ankyrin bound at its Cterminus, obscurin effectively connects titin to the sarcoplasmic reticulum (Bang et al., 2001;
Young et al., 2001; Armani et al., 2006; Kontrogianni-Konstantopoulos et al., 2009) (Fig. 6).

9

Figure 6. Schematic representation of the structure and binding partners of the two main isoforms of
obscurin, isoforms A and B. Note that the key provided lists the domain types as well as the meaning of
the colors and shapes used in the schematic (adapted from Kontrogianni-Konstantopoulos, 2009).

The OBSCN gene is located on human chromosome 1q42 (Fukuzawa et al., 2005).
Obscurin A is encoded by this gene and all other obscurin isoforms result from alternative
splicing of this gene (Russell et al., 2002; Fukuzawa et al., 2005; KontrogianniKonstantopoulos et al., 2009). Obscurin is found mostly in skeletal and cardiac muscle tissue,
though it has also been found in the brain and in breast epithelial tissue (Nagase, 2000 (1-3);
Stroka et al., 2016; Perry et al., 2014; Shriver et al., 2016). The two largest, muscle-specific
isoforms are obscurin A (~720 kDa) and obscurin B (~870 kDa). These two isoforms differ
only at the C-terminus: obscurin has a non-modular C-terminus with binding sites for small
adaptor proteins called ankyrin and obscurin B has adhesion motifs superseded by two terminal
serine-threonine kinases (Ackermann et al., 2014; Fukuzawa et al., 2005). Obscurin B has more
signaling moieties and, because obscurin has been known to directly phosphorylate substrates
in the body, this lab uses obscurin B in its experiments (Shriver et al., 2016; Perry et al., 2014;
Hu and Kontrogianni-Konstantopoulos, 2013).
Mutations in the regions close to
obscurin/titin interactions are associated with
pathogenesis of muscle diseases, namely
muscule wasting diseases such as muscular
dystrophy (MD) (Hackman et al., 2002; Zheng
et al., 2015) and malformed muscle diseases
like hypertrophic cardiomyopathy (HCM)
(Satoh et al., 1999; Fukuzawa et al., 2005). MD
is a group of inherited diseases in which
muscles become damaged and progressively
weaken. As a result, the body is unable to
increase muscle mass or repair damaged muscle
and the muscle may eventually die (Fig. 7).
Affected muscles can include skeletal and
cardiac
muscles, which can lead to problems
Figure 7. Normal muscle (left) next to a
with posture, ambulation (walking), cardiac,
muscle with muscular dystrophy (right). In the
muscle with MD, the muscle had begun to
and respiratory function (McNally and Pytel,
atrophy and is smaller in mass.
2007). HCM, on the other hand, is characterized
by a left ventricular hypertrophy with diastolic
dysfunction, all of which are caused by mutations in genes that code for proteins in the Z-band
of the sarcomere (Arimura et al., 2006; Frenneaux, 2004). In HCM, there is an asymmetric
accumulation of poorly functioning, enlarged, cardiomyocytes, specifically in the left ventricle,
which results in a constricted, generally malfunctioning heart (Fig. 8; Elliot and McKenna,
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2004; Teekakirikul et al., 2012). HCM accounts for 1% of annual mortality rates and can cause
death from sudden cardiac death, heart failure, or stroke (Frenneaux, 2004).
Obscurin mutations and pathogenesis of
muscle diseases are not as well studied as their
counterparts in titin. In fact, only a single study
involving a single example has been published
(Arimura et al., 2007). In this study, the R8 to
Q8 (Arg4344Gln) mutation in Ig58 was linked
to HCM. This mutation occurs in the OBSCN
gene in the region of that codes for the
titin/obscurin binding site and, as such, causes a
decreased binding affinity of obscurin to titin
(Arimura et al., 2007; reviewed in
Kontrogianni-Konstantopoulos et al., 2009). In
Figure 8. Normal heart (left) next to a heart
an unpublished study, a single mutation in
with hypertrophic cardiomyopathy (right). In
obscurin was linked to MD: R16 to W in Ig59
the heart with HCM, the cardiac muscles
(Rossi et al., submitted).
have enlarged and decreased the area
available for blood to flow.

X-Ray Crystallography
In order to understand the causes of these diseases on the molecular level, the wild-type and
mutated structures of these individual domains must be studied, elucidated, and compared. High
resolution structures of individual domains can be determined via nuclear magnetic resonance
(NMR) spectroscopy and X-ray crystallography.
X-ray crystallography first requires the growth of a single protein crystal, a periodic
assembly of protein molecules held together in a regularly-repeating lattice network by weak
molecular forces (Rupp, 2010). This can be accomplished through methods such as hanging
drop vapor diffusion, sitting drop, or microbatches (Rupp, 2010; Dessau and Modis, 2011).
Once the crystals are grown, they are harvested and kept frozen until data collection, generally
by use of a synchrotron. The structure of the repeating units within the crystal can be
determined by analyzing the diffraction of high energy electromagnetic radiation by the
electron density within the crystal lattice in the form of the crystal’s X-ray diffraction pattern.
When X-ray photons encounter these electrons, they are scattered at specific angles, whose
points or positions can be interpreted as reflections from sets of discrete lattice planes. This is
partially because the X-ray wavelength used is comparable to the interatomic distances in the
molecules studied (Wladawer et al., 2013). The angle of scattering is related to the distance
between planes h, k, and l by Bragg’s law, given below.
nλ = 2dhklsinθ
In which dhkl is the lattice plane spacing, n is the order of reflection, and θ is the scattering
angle.
The scattering function (𝑓𝑠 or 𝐹𝑠 ) can give the approximate X-ray scattering of an entire
system where Fs depends on the direction of scatter and, therefore, on the angle of scatter. For a
single atom, the X-ray scattering is very small and is given by:
𝑉(𝑎𝑡𝑜𝑚)

𝐹𝑠 = ∫𝑟

𝜌(𝑟)𝑒 2𝜋𝑆𝑟 𝑑𝑟
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In which ρ(r) is the electron density, r is the position of an electron in the atom, S is the
scattering vector— the difference between the incoming and scattered wave vectors— and
V(atom) is the volume of the atom. For a larger, repeating structure such as a molecular crystal
lattice, the scattering function is described as a sum of the scattering functions of individual
atoms:
𝑎𝑡𝑜𝑚𝑠

𝐹𝑠 = ∑

𝑗=1

0 2𝜋𝑖𝑆𝑟𝑗
𝑓𝑠,𝑗
𝑒

In which 𝐹𝑠 is the scattering function of the crystal and 𝑓𝑠0 is the atomic scattering factor.
The X-ray diffraction pattern can also be interpreted as transforming the crystal
structure’s electron density from real space ℝ (x, y, z) to reciprocal space ℝ* (h, k, l). In
reciprocal space, the scattering function of a molecular crystal becomes:
𝑎𝑡𝑜𝑚𝑠
0 2𝜋𝑖ℎ𝑥𝑗
𝐹ℎ = ∑ 𝑓𝑠,𝑗
𝑒
𝑗=1

In which 𝐹ℎ is the scattering function in terms of the index vector ℎ, 𝑥 denotes the position of
an atom/electron in an atom in fractional coordinates, and, by extension, 𝑥𝑗 denotes the position
of the 𝑗th atom/electron (Rupp). Such a transformation from real to reciprocal space is termed a
Fourier transform and can be generalized with the form:
∞

𝐹(𝑘) = ∫ 𝐺(𝑥)𝑒 2𝜋𝑖𝑘𝑥 𝑑𝑥
−∞

a complex Fourier integral, derived as an eigenfunction of the Sturm-Liouville eigenvalue
problem with periodic boundaries (Rupp, 2010). There is an inverse relationship between the
spacing of reflections in a diffraction pattern and the spacing in the original crystal lattice,
which can be used to establish the dimensions of a unit cell within the crystal lattice (Rhodes,
2006).
The points of a diffraction pattern give the relative intensities of scattering as well as the
position. Because the structure of the unit cells of a crystal repeats periodically to form a lattice,
the incoming photon waves that scatter as a result of an electron cloud encounter each other and
can interfere constructively, destructively, or partially, resulting in an enhancement or
quenching of X-ray radiation that is depending on the direction of the wave vector (Wlodawer
et al., 2008; Wlodawer et al., 2013). These intensities are related to the complex structure factor
(𝐹) in the following way:
𝐼 = 𝐹𝐹 ∗ = |𝐹|2
Because F is a wave equation, it must specify the frequency, amplitude, and phase of
each diffracted ray (Rhodes, 2006). But, in calculating the amplitude of the structure factor to
gain information about the intensities of a reflection, all information about the phase angle of
each reflection is lost. This significantly encumbers the reconstruction of molecular structure,
which requires an understanding of the phases of a reflection (Rupp, 2010). The remedy to this
problem will be discussed later.
The size of the unit cell of a crystal lattice is directly proportional to the number of
diffracted beams, and, therefore, is directly proportional to the number of reflections and
reflection intensity observed. Also, due to the symmetric nature of crystals, multiple individual
measurements of intensity are expected to calculate the same, unique reflection and contribute
12

to a certain redundancy or multiplicity factor. The higher the multiplicity factor, the more
accurate the average reflection intensity, since all individual reflections have an innate degree
of random error (Wlodawer et al., 2013). The value Rmerge reports the agreement of all
symmetry-equivalent reflections that contribute to the same unique reflection and is given by:
𝑅𝑚𝑒𝑟𝑔𝑒 = ∑ ∑|< 𝐼ℎ > −𝐼ℎ,𝑖 | ∑ ∑ 𝐼ℎ,𝑖
ℎ

𝑖

ℎ

𝑖

In which h represents the unique reflections, i represents the symmetry-equivalent contributors
to each unique reflection, and < 𝐼ℎ > represents the average intensity of each reflection
(Wlodawer et al., 2013; Wlodawer et al., 2008). In other words, Rmerge compares the average
intensity of the original model with the intensity of the current model and therefore is an
indicator of bias, and, consequently, potential inaccuracies. Rmerge can also be written as:
∑ℎ ∑ 𝑁
𝑖=1|𝐼ℎ,𝑖 −< 𝐼ℎ >|

𝑅𝑚𝑒𝑟𝑔𝑒 =

∑ ℎ ∑𝑁
𝑖=1 𝐼ℎ,𝑖

In which N represents all redundant measurements for each individual reflection h (Rupp,
2010). Ideally, a high-quality diffraction pattern would have an Rmerge of ≤5% (Wlodawer et
al., 2013; Wlodawer et al., 2008). However, in reality, the Rmerge may be slightly higher, though
it is generally less than 20% for large biomolecules (Rupp, 2010). Additionally, the signal to
noise ratio, < 𝐼/𝜎(𝐼) >, is defined as:
𝑁

𝐼
1
𝐼ℎ
<
>=
∑
𝜎(𝐼)
𝑁
𝜎(𝐼ℎ )
ℎ

Where an acceptable range of < 𝐼/𝜎(𝐼) > is ≤1.5-2.0 (Rupp, 2010).
In short, from the diffraction pattern, it is possible to gain the positions and intensities of
individual reflection but not their phases. The inability to garner phases from diffraction data
gives rise to the ‘phase problem’ of crystallography. Phases can be supplied by other means,
such as isomorphous replacement, anomalous scattering, and molecular replacement. The
research in this thesis was conducted using molecular replacement.
Molecular replacement uses the phases and structure factors from previously solved,
similar protein structures, called phasing models, to obtain the phases of the target protein. For
example, most if not all immunoglobulin domains are comprised of very similar structures (see
Fig. 6). Therefore, it is feasible to use phases from other immunoglobulin domains to estimate
the phases of an unsolved immunoglobulin domain; generally an immunoglobulin phase model
requires a minimum of 30% sequence identity (Scapin, 2013; Chothia and Lesk, 1986). In this
case, the two structures are isomorphous, or share the same crystal structure. The electron
density, 𝜌(𝑥, 𝑦, 𝑧), of the target structure can be calculated from those of the isomorphous
phasing models by the following equation:
𝜌(𝑥, 𝑦, 𝑧) =

1
′
𝑡𝑎𝑟𝑔𝑒𝑡
∑ ∑ ∑|𝐹ℎ,𝑘,𝑙 |𝑒 −2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧−𝛼 )
𝑉
ℎ

𝑘

𝑙

𝑡𝑎𝑟𝑔𝑒𝑡
𝐹ℎ,𝑘,𝑙

In which V is the volume of the unit cell,
is the amplitudes of the scattering function of
′
the target protein, 𝛼 is the phases of the model, and the frequencies h along the x-axis, k along
the y-axis, and l along the z-axis are given by hx, ky, and lz, respectively (Rhodes, 2006). Using
the above equation, the electron density for the entire structure can be obtained giving a map of
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the overall structure. To this, the target sequence of amino acids can be fit, giving a model of
the overall structure. Given that the first output map will be crude, because the phases of the
model are only rough estimates, both the map and model will require iterative manual and
computational improvement. However, due to the implementation of the phasing model, a great
potential for bias was also introduced— that the calculated phases from the model, rather than
the observed phases from the experimental intensities, would dominate the outputted map. To
prevent model bias, a new map can be generated by obtaining a contour in which the calculated
structure factor amplitudes (|𝐹𝑐𝑎𝑙𝑐 |) are subtracted from multiple observed structure factor
amplitudes (𝑛|𝐹𝑜𝑏𝑠 |):
𝜌(𝑥, 𝑦, 𝑧) =

1
′
∑ ∑ ∑(|𝐹𝑜 | − |𝐹𝑐 |𝑒 −2𝜋𝑖(ℎ𝑥 +𝑘𝑦 +𝑙𝑧 −𝛼𝑐𝑎𝑙𝑐 )
𝑉
ℎ

𝑘

𝑙

′
In which 𝛼𝑐𝑎𝑙𝑐
is the phases of the model. The map generated from the previous equation is
known as a 𝐹𝑜 − 𝐹𝑐 map or basic difference map and gives regions of positive and negative
densities that require moving atoms towards or away from the regions, respectively (Rhodes,
2006; Rupp, 2010). An amino acid in an unfavored conformation according to the 𝐹𝑜 − 𝐹𝑐 map
will have negative density at its current conformation and positive density nearby, where its
preferred conformation would fit.

𝐹𝑜 − 𝐹𝑐 maps rely solely on the original data and eliminate bias from the current model
so that the errors in it can be determined. Since 𝐹𝑜 − 𝐹𝑐 maps point out the errors of the current
model, it is often not useful for the beginning stages of reconstruction, when there are more
errors, because the output is ‘noisy’ and difficult to read. Therefore, a 2𝐹𝑜 − 𝐹𝑐 map or
combined difference map is more often used, which allows a greater influence from the model
but gives a more easily understood map. 2𝐹𝑜 − 𝐹𝑐 maps are given by:
𝜌(𝑥, 𝑦, 𝑧) =

1
′
∑ ∑ ∑(2|𝐹𝑜 | − |𝐹𝑐 |𝑒 −2𝜋𝑖(ℎ𝑥 +𝑘𝑦 +𝑙𝑧 −𝛼𝑐𝑎𝑙𝑐)
𝑉
ℎ

𝑘

𝑙

Through the process of model and map refinement, the particular conformation(s) of
each amino acid will be found and corrected through adjustment of variables such as clash
scores and χ and φ angles, definition of the electron density map, and decrease R-factor values,
which are defined as:
𝑅𝑓𝑎𝑐𝑡𝑜𝑟 =

∑ℎ ∑𝑘 ∑𝑙|𝐹𝑜𝑏𝑠 − 𝐹𝑐𝑎𝑙𝑐 |
∑ℎ ∑𝑘 ∑𝑙 𝐹𝑜𝑏𝑠

There are a variety of R-factors, including the linear merging R value, 𝑅𝑚𝑒𝑟𝑔𝑒 , defined
previously, which compares the average intensity of the original data and current model, and
the cross validation R value, 𝑅𝑓𝑟𝑒𝑒 , which is calculated the same as the normal R-factor but
only for approximately 10% of the original data points. 𝑅𝑓𝑟𝑒𝑒 is given by:
𝑅𝑓𝑟𝑒𝑒 =

∑ℎ𝜖𝑓𝑟𝑒𝑒|𝐹𝑜𝑏𝑠 − 𝑘𝐹𝑐𝑎𝑙𝑐 |
∑ℎ𝜖𝑓𝑟𝑒𝑒 𝐹𝑜𝑏𝑠

Where ℎ𝜖𝑓𝑟𝑒𝑒 denotes the excluded cross-validation set (Rupp, 2010). A high-resolution
crystal structure is defined by an 𝑅𝑓𝑟𝑒𝑒 < 20%, a resolution of 0.86–1.5 Å, and an 𝑅𝑚𝑒𝑟𝑔𝑒 <
~4%, though, practically, these values may deviate (Wlodawer et al., 2008). At this point, a
structure is considered ‘done’ and can be published.
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In this work, the high resolution structure of obscurin Ig59 was obtained. Work is in
progress for the elucidation of high resolution structures of obscurin domains Rho-GEF, RhoGEF-PH, kinase I (KI), and kinase II (KII).
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A Variant in the Obscurin Gene Associated with a Frameshift Mutation in the Filamin C
Gene in a Family with Distal Muscular Dystrophy*
*This chapter is based on a manuscript that has been submitted to PLoSONE. The writing of
this chapter was a joint effort between our lab and our collaborators in Italy.

Introduction
Distal muscular dystrophies are a group of inherited primary muscle disorders showing
progressive muscle atrophy and weakness, usually in the hands and/or feet (Mutoni and Wells,
2007; Ng et al., 2012; Sewry, 2010; Udd, 2012). These dystrophies have diverse etiologies, and
are further classified via one of four methods: i) clinical features, i.e. early or late adult onset,
onset in the hands or feet; ii) magnetic resonance imaging (MRI)-based evidence of an
involvement of the
anterior or posterior
Table 1. Classification and genes associated with distal muscular
compartment of the
dystrophies.
Type of Distal Muscular Dystropy
Autosomal Dominant: Late Onset
TIA1 Mutated Welander Distal Myopathy
Titin Mutated Tibial Muscular Dystropy
Distal Myotilinopathy
ZASPopathy
MATR3 Mutated VCPDM
VCP Mutated Distal Myopathy
aB-crystallin mutated distal Myopathy
Thenar Atrophy with Sarcoplamic Bodies
Mutated Distal Myopathy
Autosomal Dominant: Adult Onset
Desminopathy
ABD-FLNC Mutated Distal Myopathy
DNAJB6 Mutated Distal Myopathy
HSPB8 Mutated Neuromyopathy
Finnish MPD3
Oculopharyngeal Distal Myopathy
Autosomal Dominant: Childhood Onset
Distal Myosinopathy MYH7
KLHL9 Mutated Distal Myopathy
Autosomal Recessive: Early Adult Onset
Miyoshi Dysferlinopathy
Distal Anoctaminopathy
GNE Myopathy
Recessive Distal Titinopathy
Autosomal Recessive: Childhood Onset
Distal Nebulin Myopathy
ADSSL Mutated Distal Myopathy
Oculopathyngeal Distal Myopathy

Associated Gene
TIA1
TTN
MYOT
LDB3
MATR3
VCP
CRYAB
FHL1
SQSTM1
DES
ABD-FLNC
DNAJB6
HSPB8
No known gene
No known gene
MYH7
KLHL9
DYSF
ANO5
GNE
TTN
NEB
ADSSL1
PABPN1
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legs; iii) inheritance
pattern; and/or iv)
histopathological
findings (Udd, 2012;
Mastaglia and
Laing, 1999). Here
we will use a
combination of all
four classification
schemes to describe
a new gene member
(obscurin) that
appears to be
autosomally-linked
with late onset of
distal muscular
dystrophy (see
Table 1 for a
complete list of
other genes
involved).
In contrast
with proximal
muscular
dystrophies, in
which the mutated
genes often encode
sarcolemmal
proteins, many of
the genes identified
in distal muscular
dystrophies encode
proteins associated

with the contractile apparatus and Z-disk of the sarcomere (Udd, 2012; Udd, 2001). Both
dominant and recessive mutations in the titin gene (TTN) have been associated with human
distal dystrophies (Evilä, 2014). Titin is the largest protein of the sarcomere extending from the
Z-disk to the M-line. A number of sarcomeric and signalling proteins interact with titin (Gautel,
2011). Among these, obscurin, another giant myofibril-associated protein, interacts with titin at
both the M-band and the Z-disk (Chauveau et al., 2014; Young et al., 2001; Fukuzawa et al.,
2008; Gautel and Djinović-Carugo, 2016; Rudloff et al., 2015). Mutations in the M10 domain
of titin, which binds the Ig1 domain of obscurin, cause tibial muscular dystrophy (TMD) or
Udd myopathy in the heterozygous state and limb girdle muscular distrophy 2J in the
homozygous state. These mutations ablate the interaction between titin and obscurin at the
sarcomeric M-band and have been proposed to cause a gradual decline in sarcomere stability
(Fukuzawa et al., 2008; Pernigo et al., 2010). Oddly, no mutations in the Ig1 domain of
obscurin have been reported so far. Obscurin and titin also interact in the Z-disk, at the Ig58/59
domains of obscurin and the Z9/Z10 domains of titin. Moreover, the obscurin variant
p.Arg4344Gln, located in the obscurin Ig58 domain, was identified as the likely cause of
hypertrophophic cardiomyopathy (HCM) in a Japanese patient (Arimura et al., 2007). This
mutation weakens the binding of obscurin to titin, thus suggesting that interactions between
these two proteins are critical for optimal sarcomere stability and muscle contraction. In a
competing line of evidence, knock-in mice carrying the p.Arg4344Gln variant develop HCM
following trans-aortic constriction intervention (Hu et al., 2017, under review). However these
studies suggest other molecular mechanisms than ablation of the canonical titin-obscurin
interaction. More recently, additional OBSCN mutations have been associated with dilated
cardiomyopathy (Marston et al., 2015). Finally, knockout mice for the OBSCN gene present an
altered localization of ankyrin B and dystrophin at costameres that is paralleled by increased
sarcolemmal fragility and reduced ability to complete intense running sessions (Randazzo et al.,
2013). Following heavy exercise, the diaphragm muscle of these mice presented inflammation
and hyper-contractures with evidence of wavy and less defined M-band and H-zone (Randazzo
et al., 2017). Together, these studies present significant circumstantial evidence that obscurin
mutations are linked to muscular dystrophies.
In this current study, we propose a new obscurin mutant that is more directly associated
to dystophies. However, this study cannot offer a direct link between obscurin and muscular
dystrophy due to a second gene also being mutated in the human cohort studied by our group.
This second gene, encoding filamin C (FLNC) is linked to myopathies inherited as a dominant
trait, which may present with different clinical and histological features (Duff et al., 2011;
Guergueltcheva et al., 2011; Kley et al., 2012). Patients with FLNC mutation have progressive
proximal muscle weakness associated with the presence of aggregates of desmin and myotilin,
among other proteins within myofibers, thus resembling typical profiles of myofibrillar
myopathy (Kley et al., 2012). Interestingly, a non-myofibrillar myopathy with distal muscle
involvement has been reported in three related families from Bulgaria carrying a frameshift
deletion in FLNC (c.5160delC). This mutation was not only detected in all patients of these
families, but also in some healthy relatives (Guergueltcheva et al., 2011). Thus, the deletion
appears to result in a loss-of-function mechanism leading to haploinsufficiency with absence of
protein aggregates.
Based on the evidence that i) OBSCN ablation results in structural and functional
alterations of skeletal muscles in mice, ii) mutations in the obscurin binding domain of titin
domain M10 are causative of TMD and LGMD2J, and iii) mutations in OBSCN have been
reported in patients with cardiomyopathy, we investigated whether mutations in OBSCN could
be also involved in skeletal muscle diseases. Our collaborators performed a mutation screening
of the OBSCN exons encoding the sites of interaction between obscurin and titin at both M17

band and Z-disk in patients affected by distal muscular dystrophy. This screening identified an
OBSCN c.13330C>T mutation, resulting in a p.Arg4444Trp substitution in the obscurin Ig59
domain. This mutation segregates with muscular dystrophy in a French family. Whole exome
sequencing (WES) of this family by our collaborators identified an additional single base
deletion in the FLNC gene (c.5161delG) causing a frameshift mutation (p.Gly1722ValfsTer61).
However, segregation analysis indicated that this FLNC mutation did not completely segregate
with the disease, as the mutation was also present in one healthy relative. These findings
resemble the results previously reported by Guergeltcheva and collaborators (Guergueltcheva et
al., 2011), where a deletion in the FLNC gene (c.5160delC) was observed in individuals with
muscular dystrophy and also in healthy individuals. WES analysis performed on the DNA from
four patients, three with the disease and one healthy, from several Bulgarian families in which
the FLNC c.5160delC was described and did not reveal any additional gene variant shared by
affected individuals. Based on our collective findings, we propose that the OBSCN
p.Arg4444Trp variant may increase the penetrance of the FLNC c.5161delG deletion in the
French family. Accordingly, variants in the OBSCN gene should be considered as potentially
causative of muscular dystrophy, alone or in association with variants in other myopathy genes.

Materials and Methods
Patient Data.† Mutation screening was initially performed in families where the affected
members presented with a clear distal myopathy phenotype transmitted as dominant trait. The
study was then extended to a cohort of 110 unrelated patients consisting of 11 cases with
predominantly proximal muscle weakness, respiratory failure and/or cardiomyopathy, 8 cases
with predominantly proximal myopathy, 26 cases with initial distal muscle involvement
subsequently progressing to proximal limb weakness, and 65 cases of patients with a clinical
history of uncharacterized muscular dystrophy/myopathy. In the French family reported here,
the proband (III:3), a woman issued from non consanguineous parents, and her second son
(IV:2), had progressive distal lower limb weakness starting at ages 30 and 14, respectively. The
proband’s father (II:2) had very late-onset walking difficulties, became wheelchair bound at age
75 and subsequently died from respiratory insufficiency and pneumonia. The paternal
grandfather (I:1) also became wheelchair-bound at an advanced age. Other family members had
no neuromuscular history. The proband and her affected son were followed in Neuromuscular
Unit of Salpêtrière Hospital (Paris, France). Among the four children of the proband, one
daughter (IV:3) and one son (IV:4), seen at the Neuromuscular Unit at age of 33 and 32,
respectively, had a normal clinical examination, with no muscle alteration as shown by MRI.
Ethics committee approval and written informed consent was obtained for all patients. This
study complies with the ethical standards stated in the 1964 Declaration of Helsinki.
Mutation Screening and Genotyping.† Mutation screening by conventional Sanger sequencing
on specific regions of OBSCN was performed in all family members for whom DNA was
available. In detail, primers were designed using Primer3 software
(http://frodo.wi.mit.edu/primer3) to amplify OBSCN exon 2 (coding for the Ig1) and exons 50,
51 and 52 (coding for the Ig58/59 domains), according to sequence NM_052843. Genomic
DNA was extracted from peripheral blood leucocytes by standard procedures (Kley et al.,
2012). Amplified DNA fragments were directly sequenced using an ABI Prism 310 apparatus
(Applied Biosystem). Alternatively, Sanger sequencing was performed using DreamTaq™
DNA Polymerase (Thermo Scientific) according to standard protocol and PCR products were
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sequenced on an ABI3730xl DNA Analyzer (Applied Biosystems), using the Big-Dye
Terminator v3.1 kit and analyzed with Sequencher 5.0 software (Gene Codes Corporation).
DNA mutation numbering was based on cDNA reference sequence (NM_052843), taking
nucleotide +1 as the A of the ATG translation initiation codon. The mutation nomenclature
used follows that described at http://www.hgvs.org./mutnomen/.
Whole Exome Sequencing (WES).† Whole exome sequencing (WES) was performed on patients
III:3 and IV:2 at ATLAS Biolabs GmbH using SeqCap EZ Human Exome Library v2.0 (Roche
NimbleGen) for DNA capture. The enriched DNA was sequenced with an Illumina HiSeq 2000
platform, 2 x 100 bp. Reads were aligned to the human genome reference GRCh37/hg19 with
Burrows-Wheeler Aligner and duplicate reads were removed with Picard. The Genome
Analysis Toolkit was used to realign the reads, recalibrate base quality scores and call variants.
Variants were annotated using wAnnovar and variants with frequency more than 1% in the
1000 Genomes or Exome Sequencing Project (ESP6500) databases were filtered out.
Remaining variants present in both III:3 and IV:2 were analyzed.
WES on 3 patients and a normal relative from the Bulgarian families (Guergueltcheva et
al., 2011), was performed at Centro di Ricerca Interdipartimentale per le Biotecnologie
Innovative (CRIBI), Padova, Italy. DNA libraries for WES were constructed following the
standard protocol of the Ion AmpliSeq™ Exome RDY Kit (ThermoFisher Scientific). Starting
from 100 ng of gDNA, a multiplex-PCR with 12 primer pools was performed in order to allow
the amplification of 24,000 amplicons per pool, covering the exonic regions of the genomes
(about 58 Mb). 9 µl of 100 pM barcoded libraries were amplified by emulsion PCR using a
OneTouch2 instrument. Finally, the barcoded samples were loaded into Ion Proton P1 v3 chip
and sequenced on the Ion Proton instrument using the Ion Proton HiQ Sequencing kit. The
bioinformatic analysis was performed on the Ion Torrent Server and the Torrent SuiteTM was
used to base-call and align the reads to the human reference genome (GRCh37/hg19).
Alignment BAM files, Coverage Analysis statistics and Variant Analysis VCF files were
produced. By default, the variant calling was performed using the “Germ Line-High
Stringency” algorithm.
Generation of GST Expression Vectors and Constructs for in vitro Translation.† Human
OBSCN cDNA (NM_052843) coding for Ig58/59 was amplified from total RNA extracted from
human skeletal muscle tissue using specific primers (forward primer: 5’- aagaacacggtggtgcggg
– 3’; reverse primer: 5’- gaggcccagcagggtgagc-3’). The OBSCN cDNA containing the
c.13330C>T variant was generated by PCR using primers designed to introduce the cytosine to
thymine nucleotide change into the wild-type cDNA (forward primer: 5’aacgcggcggtcTgggccggcgcacag – 3’; reverse primer: 5’- ctgtgcgccggcccAgaccgccgcgtt-3’) and
sequenced using an ABI Prism 310 apparatus (Applied Biosystems). The amplified sequences
were cloned into the vector pGEX (GE Healthcare) using the EcoRI-SalI sites to generate GSTOBSCNWT and GST-OBSCNMUT fusion proteins. Human TTN cDNA (NM_001267550) was
amplified from total RNA extracted from human skeletal muscle tissue using specific primers.
The TTN cDNA containing the Z9/Z10 domains of TTN was generated by PCR using the
following primers (forward primer: 5’ - gacaaagagaaacaacagaaa – 3’; reverse primer: 5’ –
atcttccctctgttgaatctc – 3’) and sequenced using an ABI Prism 310 apparatus (Applied
Biosystems). The amplified sequences were cloned into the vector pGBK-T7 in frame with a
myc tag epitope (Clontech) using the EcoRI-SalI sites.
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Protein Expression and in vitro Interaction Studies.† GST fusion proteins grown in Escherichia
coli (E. coli) (BL21(DE3)) were induced at OD600=0.6 with 1 mM isopropyl β–Dthiogalactopyranoside (IPTG) for 3 hrs at 30°C. Cells were harvested centrifugation at 4000 xg
for 10 min at 4°C. The pellet was resuspended in cold buffer containing Phosphate Buffer
Saline (PBS), 1% Triton X-100, 20 mM EDTA and lysed by sonication on ice. The soluble
fraction was obtained by centrifugation at 13200 xg for 15 min at 4°C. The fusion proteins were
immobilized by incubating 1 ml of the soluble fraction with 100 µl of glutathione-Sepharose 4B
resin (GE Healthcare, Buckinghamshire, United Kingdom) for 10 min and washed three times
with 1 ml of a buffer containing PBS and 1% Triton X-100 (Rossi et al., 2014a). Beads were
finally resuspended with an equal volume of PBS and the protein was eluted from the column
with glutathione-PBS buffer.
In vitro translation and transcription experiments were performed using the TNT Quick
Coupled Reticulocyte Lysate System as described by the manufacturer (Promega). 5 µl of the
translation reaction were incubated with 12 µg of GST fusion protein in a buffer containing 10
mM Tris-HCl pH 7.9, 150 mM NaCl, 0.5% NONIDET P-40, 1 mM DL-Dithiothreitol (DTT), 1
mM phenylmethylsulfonyl fluoride (PMSF) and protein inhibitor mixture for 1.5 hrs at 4° C.
After incubation, the GST fusion protein complexes were washed 3 times with interaction
buffer. Bound proteins were eluted by boiling in sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer and analysed by SDS-PAGE.
Western Blot Analysis. Protein samples were separated by 10% SDS-PAGE. Filters were
incubated with primary antibody (mouse anti-c-myc, Clontech-Zymed Laboratories Inc.), and
diluted in blocking buffer overnight at 4°C with agitation. Filters were washed three times with
washing buffer (0.5% non-fat dry milk, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Tween20) for 10 min each, incubated with horseradish peroxidase-conjugated secondary antibody and
detected using the ECL system (ECL Western Blot Detection Reagents, Promega).
Nuclear Magnetic Resonance (NMR) Preparation and Data Collection. All chemicals were
ACS grade or higher and were typically purchased from Fisher Scientific unless otherwise
specified. Recombinant 15N, 15N-13C, and unlabeled protein were purified after overexpression
in BL21 cells using a pET24a vector system (Novagen, San Diego CA) in a manner similar to
(Rossi et al., 2014b). All nuclear magnetic resonance (NMR) experiments were collected on a
600 MHz Bruker Avance II spectrometer equipped with a TXI room temperature 5 mm probe
with z-axis pulse field gradient coils. All NMR samples were collected at 25 C in 20 mM Tris
pH 7.5, 20 mM NaCl, 0.35 mM NaN3, and 0.5-2.5 mM protein with 10% D2O. All 2D and 3D
NMR experiments were collected as previously described (Rossi et al., 2014b). Further
description of NMR collection is located in the supplemental information. Chemical shifts for
Ig59 have been deposited in the Biological Magnetic Resonance Bank (BMRB) under
accession number 26593.
A 2D HSQC was collected, as well as standard triple resonance experiments including
HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, C(CO)NH, H(CCCO)NH, 15N-edited
TOCSY, 15N-edited NOESY, 13C-edited NOESY, and pseudo-3D IPAP experiment for H-N
residual dipolar couplings, as previously described (Rudloff et al., 2015). Both NOESY
experiments used 110 ms mixing time. Most experiments were collected with 128, 64 and 1024
points in the T1, T2, and T3 dimensions, respectively. NMR data were processed with
NMRPipe (Muntoni, 2007), extended in the indirect dimension via linear prediction, and the
resulting spectra were analyzed via Sparky (Lee et al., 2015).
Standard Bruker IPAP experiments using 256 points for each T1 dimension were used
to collect RDC data in isotropic and axially-compressed 5.5% acrylamide gel samples, as
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previously described (Ng et al., 2012). The program PALES was used for RDC alignment
tensor fitting with a calculated Aa and Ar component of 0.00163 and 0.000901, respectively
(Sewry, 2010). For all experiments, the 1H chemical shifts were referenced to external DSS, the
13C shifts were referenced indirectly to DSS using the frequency ratio 13C/1H = 0.251449527
and 15N shifts were referenced indirectly to liquid ammonia using 15N/1H = 0.101329118.
NMR Structure Calculation. Interproton distance constraints were derived from 3D NOESY
experiments (15N-edited and 13C-edited 3D NOESY) as described previously. Dihedral
constraints  ± 20˚ and ψ ± 15˚ for -helix and  ± 40˚ and ψ ± 40˚ for -sheet were included
based on TALOS+ and the chemical shift index of 1H and 13C atoms (Rudloff et al., 2015).
Residual dipolar coupling data was included based on splitting values from an IPAP
experiment, as previously described (Shen et al., 2009). More information about the structure
calculations can be found in the supplemental information. The final 20 structures were selected
(from 200) based on lowest Q-values and lowest root mean squared deviation (RMSD) from the
average, and were of high quality based on the statistical criteria listed in supplemental Table 3.
The coordinates of the human OBSCN Ig59 structure have been deposited in the Protein Data
Bank (2N56).
An ensemble of structures without dihedral restraints had a backbone RMSD of 0.85 Å
when compared to structures with dihedral constraints (Udd, 2012). We attempted to further
verify the structure by performing a H-D exchange experiment, however this Ig domain
remains unfolded after lyophilization. Therefore, hydrogen bond constraints were not tested
directly but instead were added into the structure only after the secondary structure was
completely determined. Structures calculated without hydrogen bonds had an RMSD of 0.59 Å
when compared to those calculated with hydrogen bonds, indicating that inclusion of these
bonds did not drastically influence the overall structure. Hydrogen bond constraints of rHN-O =
1.5 Å to 2.8 Å and rN-O = 2.4 Å to 3.5 Å were included in the final stage of structure
calculations, and were based off regions that were clearly in well-defined secondary structural
motifs. Pseudopotentials for secondary 13Cα and 13Cβ chemical shifts and a conformational
database potential were included in the final simulated annealing structural calculations using
the computer program XPLOR-NIH (Mastaglia and Laing, 1999; Udd and Griggs, 2001).
Structures run with and without these pseudopotentials show an RMSD of 0.58 Å. The
internuclear dipolar coupling (in Hz) were determined from the difference in J splitting between
isotropic and radially compressed polyacrylamide, and were incorporated into the final
structure calculation as previously described using an energy constant of 0.50 (Evilä et al.,
2014; Gautel, 2011). A comparison of structures run with and without RDC measurements
show an RMSD of 0.67 Å. Q-factors were calculated by randomly removing ≈ 10% of the NHN RDC data, and then comparing these values to those back-calculated from the structure.
Purification of Obscurin Ig59. Protein samples of pet-24a(+) human obscurin Ig59 were
expressed in E. coli and purified through the following procedure. Starter cultures (~5mL) of
Ig59 were made following addition of glycerol stock (500ul Ig59 PEP24A BL-21 cells into
50/50 glycerol) and 10ul of kanamycin. Starter cultures were shaken overnight at 37C, 250rpm,
then added to 1L flasks of Luria broth (LB) (10g tryptone, 5g yeast extract, 5g NaCl, dilute to
volume with diH2O) along with 1mL kanamycin. These flasks were also shaken at 37C,
250rpm. Induction occurred ~3hr later, at 0.6-0.8 OD, with the addition of 0.2g IPTG.
Approximately 3hr later, flasks were taken out of the incubator/shakers and centrifuged using a
JLA 16.250 rotor at 6000rpm, 4°C for 15min. The supernatant and pellet were separated and
the pellet was kept at -80°C until ready for further purification. Pellets were resuspended in
G75 buffer (20 mM Trist, 50 mM NaCl, azide) and 100ul PMSF was added to prevent
degradation during sonication at 100% amplification, 15s pulse, for 30min, then centrifuged
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using a JA 25.50 rotor at 14000rpm, 4°C for 30min. The supernatant was run over a Nickel
column and the eluent was concentrated in a 5K concentrator tube via centrifugation at
4500rpm for 90min intervals until less than 1mL solution remained, then run over a size
exclusion column. Contents of column fractions were visualized using gel electrophoresis;
fractions containing Ig59 were pooled and concentrated. The concentration of Ig59 in the
resulting solution was obtained using a Thermo Scientific Nanodrop 2000 Spectrophotometer
using the extinction coefficient (12490 cm-1M-1) and molecular weight (11.1 kDa) of Ig59.
Crystallization and X-ray Diffraction. The hanging drop method with 17% tacsimate, 0.1M
HEPES pH 7.5, 4%
Table 2. Final refinement statistics of human obscurin domain Ig59.
PEG3350, and 10 mg/mL
Parentheses indicate the statistics of the outer shell.
protein was used to obtain
Ig59 crystals. Crystals were
Wavelength (Å)
0.97918
harvested and frozen in
Resolution range (Å)
30.49 - 1.177 (1.219 - 1.177)
liquid nitrogen after one
Space group
P 31 2 1
week using a glucose
Unit cell (Å)
60.98 60.98 47.56 90 90 120 cryoprotectant and
Unit cell (°)
90 90 120
crystallographic reflections
were collected at the
Total reflections
662701 (35265)
Structural Biology Center
Unique reflections
33764 (3303)
beamline 19-ID-D at the
Multiplicity
19.5 (10.7)
Advanced Photon Source,
Completeness (%)
98.82 (92.53)
Argonne National
Mean I/sigma(I)
22.98 (5.07)
Laboratory. HKL2000 data
processing calculated the
Wilson B-factor
14.83
unit cell to be P 31 2 1
R-merge
0.1345 (0.5394)
(Otwinosky and Minor,
R-meas
0.1389
1997).
CC1/2
0.988 (0.912)
Structure refinement.
CC*
0.997 (0.977)
Crystal diffraction phasing
R-work
0.1642 (0.2634)
was determined using the
R-free
0.1851 (0.2974)
program Phaser-MR in the
Number of non-hydrogen
775
PHENIX ver 1.72.2-869
atoms
program suite via molecular
macromolecules
678
replacement using PDB and
ligands
0
reflection files from
accession numbers 2YZ8
water
97
and 4RSV. The resulting
Protein residues
90
structure was refined using
RMS(bonds)
0.033
the program PHENIX ver.
RMS(angles)
1.46
1.72.2-869-refine (Afonine
Ramachandran favored (%)
99
et al., 2012). COOT was
used to manually rebuild the
Ramachandran outliers (%)
0
structure in iterative rounds
Clashscore
2.23
of rebuilding and refinement
Average B-factor
20.5
in PHENIX refine, resulting
macromolecules
19.4
in a 1.18 Å resolution
ligands
0
structure with an Rfree value
solvent
28.3
of 0.185 (Emsley et al.,
2010). More refinement
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statistics are given in Table 2. The coordinates of Ig59 have been deposited in the PDB under
accession number 5TZM.
Molecular Dynamics Modelling. Coordinates corresponding to the crystal structure of Ig59
were allowed to equilibrate using YASARA 12.7.16, at 310K, 150 mmol/L NaCl, pH 7.4, using
the Amber ff03 forcefield in a simulation cell with periodic boundaries until the backbone
RMSD no longer changed significantly (Wright et al., 2005). Simulations were run with a
timestep of 1.25 fs with the temperature adjusted using a Berendsen thermostat as described by
Krieger et al. (Krieger et al., 2014; Kireger et al., 2004). Once finished, the p.Arg4444Trp
mutation was introduced to the simulation using the ‘swap’ function in YASARA. This mutated
structure was then once again allowed to equilibrate using the same parameters as for the wildtype structure, and the simulation was terminated when the RMSD stabilized. YASARA and
Pymol were used to visualize the structures (de Groot et al., 1997; The PyMOL Molecular
Graphics System).
Circular Dichroism. All CD experiments were conducted in a 1 mm pathlength cuvette at 15
μM protein in 20 mM Tris buffer, pH 7.5 and 100 mM NaCl. Samples were measured in
triplicate at 37°C on a Jasco J-810 spectrophotometer.

Results
Clinical Findings. † Our collaborators performed quantitative studies on human patients with
dystrophies in order to investigate the disease. The proband (III:3) of these studies was a 61year-old female presenting a progressive distal dystrophy since around age 30, affecting
successively the right hand and progressing slowly to include both distal upper and lower limbs.
At age 45, difficulties in standing up from a chair and a steppage gait appeared. At age 51,
ambulation was not limited, but the patient exhibited foot drop (more pronounced on the right
side), inabilities to stand on tip toes or heels, and a waddling gait. Hand finger extensors, foot
evertors, toe extensors, and calf muscles showed severe weakness, but finger flexors and the
tibialis anterior were normal. Glutei maximi, thigh adductors, and hamstrings were also
severely affected, but proximal scapular, brachial, and antebrachial involvement was not
detected. Hand palmar muscles (mainly thenar ones), calves and tibial muscles were atrophic
(Fig. 1A1-5). In addition to the worsening myopathy, a progressive cervical myelitis of
unknown aetiology appeared at age 52, manifesting as a sensory defect mainly in left lower
limbs and spreading from foot to hip, causing severe pains and impaired balance. At age 61, she
could walk slowly a few hundred meters with two aids. The previously described clinical
selective pattern was found with severe wasting of hand finger extensors, toes extensors,
peroneus lateralis, posterior calf muscles, and hamstrings. Hand finger flexors, tibialis anterior,
quadriceps, along with scapular, brachial, antebrachial, axial, facial and oculo-bulbar muscles
remained mostly spared. Quantitative measurements are detailed in Table 3. A sensory defect
due to the myelopathy was found in both distal and proximal lower limbs (left > right). Creatine
kinase (CK) levels were normal. Electromyogram (EMG) showed myopathic changes distally
in the upper limbs and both proximally and distally in the lower limbs. Cardiac evaluation
†Work

of Dr. Vincenzo and collaborators

(ECG and echocardiography) and spirometry were normal. Spinal cord MRI performed at age
53 revealed a posterior hyperdense signal from C2 to C7 (Fig. 1-C2-C7). Brain MRI and CSF
were normal.
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Our collaborators reported that the proband’s son (IV:2) noticed first symptoms
(fatigability in walking and difficulties in standing on tip toe) at age 14. He has been unable to
run since the age of 16 years. He could walk a distance of around 1000 meters without aid at
age 33. He had marked weakness and atrophy in the calf muscles and minor weakness in the
interossei and finger extensors, but otherwise normal muscle strength in the proximal lower
limbs and in the upper limbs (Table 3). No facial or bulbar weakness was present. CK levels,
spirometry and cardiac evaluation were normal. Electromyography (EMG) showed myopathic
changes.
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Table 3. Quantitative clinical measurements performed by our collaborators documenting the progressive muscular dystrophy of the proband and her son.
Case
Age
Sex

Symptom
onset
(age in years)

Course

Current status: (age)
functional ability

Current status
Muscle weakness

Current status
Muscle atrophy

CPK/ EMG / Cardiac
echography/ EKG/ Vital
capacity

Case I
Proband
61y
F

Right hand
atrophy /
weakness
(finger
extensors)

Progressive worsening
Around 30y : both hands
wasting, inability to stand on
heels and tiptoes,
35 y
difficulties climbing stairs.
46 y Gowers, difficulties standing
from a chair, running inability.
Increased weakness of foot
evertors, hand finger extensors
52y : cervical myelitis
manifesting by left foot
extending to whole limb after 6
months. sensory defect without
identified cause (Spine MRI T2
sequence hypersignal from C2 to
C7)
(normal Brain MRI, normal CSF
fluid)
Increased loss of balance and
cordonnal pains
53 y : fallings (weakness and
balance impairment)
59 y : walk with bilateral aid

(61y)
Walking distance : few
hundreds meters with aid
Fallings, four to five
times monthly
right foot elevator
Difficult walk with
steppage and tendency to
internal rotation of feet
10 m in 15 s with a cane.
Inability to stand on heels
and tiptoes
Rising from chair 9 times
in 60 s with two hands
Thigh crossing : difficult

Legs (both
compartments)

CK normal

Arm elevation : normal

Lower limbs
Toes extensors 2, except big toe,
1 , Peroneus 1, , Tibialis anterior
4, Post legs 2+ Hamstrings 2,
Quadriceps 5Adductors 2+, Glutei maximi
2+, Glutei medii 4+, Iliopsoas 4+
Upper limbs
Finger extensors 3-, index more
affected :
right index 2, left 2+
Finger flexors 4+
wrist extensors 4
scapular and brachial 5
Axial and neck
flexors 4facial, oculobulbar normal

Painful spinal posterior
column syndrome
(myelitis)

in addition : hypoesthesia of
whole left lower limb due to
myelitis

Mild progression
At 16 y, interruption of sport at
school and inability to run.

(33y)
Walking distance : 1000
m without aid
No fallings
Climbing stairs with
banister 10 m : 12s
Rising from a chair : 24
times in 60 s without aid
Arm elevation : normal

Lower limbs
Peroneus 3-, Tibialis anterior 3+
Toes extensors between 4 , and 2
(big toe) Post legs 2
Pelvic and femoral muscles 5
Upper limbs
Finger extensors 4+,
Finger flexors 5
wrist extensors 5
scapular and brachial 5
Axial and neck
flexors 5
facial, oculobulbar normal

(≈ 30y)

Case II
Son of
case I
33 y

M

Difficulties
standing on
tiptoes and
heels
fatigability in
walking
(14y)
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Hand : palmar,
mostly thenar
region

EMG : myogenic
Distal in Lower limbs, Distal +
proximal in lower limbs
Nerve : normal
No decrement
Normal echography and EKG
VC : 85%

Legs, mainly
posterior
compartment
No atrophy of
upper limbs

CK normal
EMG : diffuse myogenic
pattern
Nerve : normal
Normal echography and EKG
VC : 86%

Muscle imaging performed by our collaborators on the mother at the age of 51 showed
severe fatty degenerative changes in almost all lower leg muscles, except for tibialis anterior,
posterior and long toe flexor muscles. The quadriceps was considerably less affected than the
hamstrings and adductors. Glutei maximi and iliopsoas were less affected than glutei minimi and
medii. The forearm extensor
muscles showed reduced volume.
At age of 61 years, this pattern
remained mostly unchanged,
except that the vastus medialis and
vastus internalis fatty degeneration
was more marked, particularly in
right side. Rectus femoris and
vastus lateralis remained spared
(Fig. 1). In the 33-year-old son, the
changes in CT scan were milder,
with the exception of severe fatty
replacement in the calf muscles
and, less severely, in the lateral
compartment peroneal muscles. All
other muscles were intact.

Figure 1. A/B) Clinical data, C) morphological studies, and
D) ultrastructutal studies of the proband (III:3). A1-3:
Evidence of muscle atrophy in thenar muscles. A4-5: All
distal leg muscles of the proband are markedly affected,
except for tibialis muscles. B1-4: Computed Tomography
(CT) of the proband at the age of 51 showed severe fatty
degeneration changes in most leg muscles. C1-C4: Radialis
muscle biopsy of proband (III:3). C1. Haematoxylin & Eosin:
presence of some nuclear internalization and fiber size
variation. C2 NADH: lobulated fibers are indicated by an
arrow; uneven staining of the intermyofibrillar network in
some fibers is indicated by a star. C3 desmin: mild diffuse
desmin surcharge in several fibers C4 myotilin.:ormal
staining. C5-C8: Peroneal muscle biopsy from the proband
son (IV:2). C5 NADH: atrophic lobulated fibers are indicated
by an arrow. C6 desmin: mild diffuse desmin surcharge in
several fibers. C7 alpha B cristallin: presence of dense
protein aggregates. C4 myotilin: normal staining. D. Radialis
muscle biopsy of proband (III:3), EM analysis. D1: presence
of numerous abnormal mitochondria harbouring dotty or
paracrystallin inclusions, in proximity of the star. D2:
presence of a cytoplasmic protein aggregate composed by
dark osmiophilic granulo-filamentous material corresponding
to desmin, indicated by an arrow, and filamentous 26
material
indicated by an asterisk.

The radialis muscle biopsy
from the proband (III:3) performed
at 51 years showed some nuclear
internalization, fiber size variation
(Fig. 1B1), and type 1
predominance. Oxidative
histoenzymatic reactions disclosed
few lobulated fibers and uneven
staining of the intermyofibrillar
network (Fig. 1-B2). Our
collaborators’ peroneal muscle
biopsy of the son (IV:2) at 33 years
showed marked fiber size
variability with the presence of
some atrophic angulated fibers (Fig.
1C1). A few lobulated fibers were
also present.
Immunohistochemistry performed
in both muscle biopsies revealed
some desmin surcharge in both
patients (Fig. 1B3, C2). In contrast
only patient IV:2 (the son of the
proband) harboured alphaB
crystallin immunoreactive
aggregates (Fig. 1C4). Myotilin
immunostaining did not show

specific alterations (Fig. 1B4, C4). Ultrastructural studies performed by our collaborators on the
proband (III:3) showed myofibrillar disorganizations resembling targetoid structures in a small
percentage of the fibers (not shown). Abnormal mitochondria with some paracristalline
inclusions (Fig. 1B5, indicated by a star) and dark dots were observed in numerous fibers. Focal
disintegration of myofibrils, dark osmiophilic granulo-filamentous material corresponding to
desmin (Fig. 1C5, indicated by an arrow) and filamentous protein aggregates (Fig. 1C5,
indicated by an asterisk) were observed in PX (or son of the proband).
However, a
subsequent WES
analysis,
performed by our
collaborators
using the DNA
from the III:3
proband,
identified an
additional novel
frameshift
mutation in the
FLNC gene
(NM_001458.4).
This was a
deletion of a
single base in
exon 30
(c.5161delG)
Figure 2. Genetic analysis of OBSCN c.13330 C>T and FLNC c.5161delG
resulting in a
mutations. A) Family pedigree. Black filled symbols represent affected family
frameshift and a
members. The genotype of individuals is shown as follows: +/+ wild type, OBSCN
+/- heterozygous for the c.13330 C>T mutation, FLNC +/- heterozygous for the
premature stop
c.5161delG mutation. Arrow indicates the proband. B) Electropherogram of the
codon
OBSCN gene sequence (upper panel) and of the FLNC gene sequence (lower
(p.Gly1722Valfs
panel). C) Phylogenetic alignment of the OBSCN orthologs. Sequences
Ter61, Fig. 2B).
represent the Ig59 domains of OBSCN in distinct mammalian species. The
Sanger
arginine in position 4444 in the human OBSCN sequence is highlighted in yellow
and is conserved in mammalian species. D) Interaction between titin domains
sequencing for
Z9/Z10 and OBSCN domains Ig58/Ig59. in vitro transcribed and translated mycFLNC exon 30
tagged titin domains Z9/Z10 were used in pull-down experiments with GST-fusion
was performed
proteins containing either wild type OBSCN Ig58/Ig59 domains (OBSCNWT) or
by our
R4444W mutated OBSCN Ig58/Ig59 domains (OBSCN MUT). Proteins were
collaborators on
separated by SDS-PAGE, transferred to membranes and detected by mouse
anti-myc antibodies. E) Quantification of GST pull-down efficiency. Protein bands
II:1, III:3, III:4,
intensities of myc-tagged Z9/Z10 titin domains precipitated by either OBSCNWT or
IV:1, IV:2 and
OBSCNMUT GST-fusion proteins were evaluated by densitometric analysis and
IV:3. The FLNC
normalized on GST fusion proteins content. Data represent means values ±
variant
standard deviation of five independent experiments in triplicate. * p < 0.01
c.5161delG was
following t-test statistical analysis.
present in the
two affected individuals (III:3, IV:2) but also in one healthy individual (IV:3). This deletion is
located adjacent to the previously reported c.5160delC deletion, which is linked to distal
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myopathy with upper limb predominance in three Bulgarian families (Guergueltcheva et al.,
2011). To investigate if the OBSCN variant identified in the French family was present also in
the Bulgarian families with recurrence of the FLNC c.5160delC frameshift, our collaborators
initially performed Sanger sequencing of exons 2, 50, 51 and 52 of the OBSCN gene in 12
individuals from the three related Bulgarian families [3 unaffected non-carriers of the FLNC
c.5160delC (2701:IV.1, 2702:III.3; 2703:IV.3), 4 asymptomatic carriers of the FLNC c.5160delC
(2701:IV16; 2701:V1; 2701:V2; 2702:IV3), and 5 individuals with distal dystrophy carrying the
FLNC c.5160delC(2701:IV3; 2701:IV.10; 2702:III.1; 2702:IV.1; 2703:III.2)]. Since this initial
screening did not identify any variant in the selected exons of OBSCN, WES analysis was
performed by our collaborators in three affected FLNC mutation carriers and one normal relative
from the Bulgarian families (patients IV:3 of family 1, III:1 of family 2, III:2 of family 3 and
individual IV:1 of family 1) Variants were filtered for a global minor allele frequency ≤0.001,
shared by the affected individuals but not present in the asymptomatic member. This analysis
identified no mutation (missense, nonsense, indel) shared by the patients and not present in the
normal relative of the Bulgarian families.
Structural Studies of the Ig59 Domain of OBSCN. From the above analysis, we reasoned that the
dual OBSCN and FLNC mutations may represent a digenic heterozygous condition, where the
OBSCN mutation leads to an increased penetrance of the FLNC mutation. In order to begin
defining the molecular mechanism of the described phenotype, we investigated how the normal
and mutated obscurin Ig59 domain interacts with its binding partner titin. We first solved the
high-resolution structure of Ig59 (residues 4428-4521). Human obscurin Ig59 was isolated based
on the original sequence alignment (CAC44768.1) (Young et al., 2001). After purification, the
beta-sheet rich structure was verified by CD, the pure Ig59 was crystallized. The resulting
crystals diffracted to a resolution of 1.18 Å (Fig. 3A, Table 2). The resulting structure shows beta
sheets extending from Glu 4435 to Lys 4438 (strand A’), Ala 4440 to Arg 4443 (strand A), Ala
4446 to Thr 4453 (strand B), Ser 4464 to Ile 4468 (strand C), Trp 4479 to Asp 4484 (stand D),
His 4487 to
Leu 4493
(strand E),
Gly 4501 to
Ala 4506
(stand F),
and Ala
4512 to Leu
4519
(strand G).
Overall, the
structure
forms a
typical Iglike fold
(Meyer and
Wright,
Figure 3: Structure and analysis of human obscurin Ig59. A) Cartoon of the Ig59 crystal
2013).
structure, showing the typical Ig-like fold. B) Comparison between the Ig59 NMR and Xray structure. C) CD plot of WT obscurin Ig58-59 (black squares) and p.Arg4444Trp
(open circles). D) MD simulated average models of WT (blue) and Arg4444Trp (red) Cα
positions. The side chains for Arg4444/Trp4444 are shown. E) RMSD vs residue
number comparison of the mutant model to the wild-type model. The Arg444Trp site is
28
shown in red.

An independently solved NMR solution structure of human obscurin Ig59 contains
greater than 12 restraints per residue (Fig. 3B, Fig. 4, Table 4). The overall backbone root mean
squared deviation (RMSD) of ordered heavy atoms is 0.609 Å. With the exception of Arg 4430,
and Arg 4508, every backbone H-N bond and most sidechain C-H shifts are visible in these
NMR experiments. H-N residual dipolar coupling experiment values independently verify the
validity of this
structure, and result
in a Q-factor of 0.25
±0.02. The NMR
and X-ray structure
have a pairwise
RMSD of 1.609 Å
(Fig. 3B). The
differences between
the two structures
are most
pronounced
between residues
Asn 4468 and Ser
4478. This area is in
a long loop region,
and is associated
with higher Bfactors in the X-ray
structure and a
lower number of
NOE restraints in
the NMR structures.
Aside from this
area, the structures
are highly similar to
each other.

Figure 4. NMR data used to determine the structure of human obscurin Ig59.
A) Observed beta sheet interactions of Ig59 as seen in the 15N-edited NOESY.
B) NOESY data (in black) overlaid with TOCSY data (in red), showing selfpeaks and cross-strand NOEs. C) Example of CBCA(CO)NH (in red) and
HNCACB (in black) experiments, showing NMR assignments. D) Example of
residual dipolar coupling data showing isotropic (right) and anisotropic (left)
examples of the H-N bond from A78.
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Table 4. NMR-derived statistics of 20 NMR structures1 of human obscurin
domain Ig59. Parenthesis indicate the number of restraints.

The
p.Arg4444Trp
mutation
RMSD from distance
2
could affect the obscurinconstraints (Å)
titin interaction in two
total (1061)
0.028 ± 0.002
0.029
ways: it may unfold the
intraresidue (228)
0.005 ± 0.004
0.003
entire Ig59 domain, or it
sequential ( |i – j| = 1) (382) 0.019 ± 0.005
0.022
may maintain the fold
medium range ( 1 < |i – j| ≤
0.046 ± 0.006
0.056
and simply perturb the
1) (95)
binding event. To
long range ( |i – j| = 1) (292) 0.031 ± 0.003
0.003
examine the effect of the
hydrogen bonds (64)
0.056 ± 0.006
0.050
p.Arg4444Trp mutation
RMSD from exptl dihedral
on the Ig59 structure, we
constraints (°)
conducted circular
Φ,Ψ (144)
0.687 ± 0.116
0.684
dichroism (CD)
RMSD from dipolar
experiments on the WT
coupling restraints (Hz)
and mutant forms of Ig59.
DNH (52)
0.89 ± 0.09
0.93
As can be seen in Fig.
RMSD from exptl 13C
3C, the CD profiles are
chemical shifts
virtually identical,
13
Ca (ppm)
1.59 ± 0.17
1.31
suggesting that the
13
Cb (ppm)
1.46 ± 0.04
1.47
mutation does not
RMSD from idealized
globally disrupt the
geometry
overall Ig-like
bonds (Å)
0.004 ± 0.001
0.004
architecture. To gain
angles (°)
0.633 ± 0.020
0.640
greater insight into the
impropers (°)
0.442 ± 0.036
0.431
local effect of the
-363 ± 10
-359
Lennard-Jones potential
p.Arg4444Trp, the WT
energy (kcal/mol)3
and mutant protein
0.27 ± 0.04
0.25
Q-value4
structures were examined
72.8
% most favorable region in 74.1± 3.0
using molecular
the Ramachandran plot5
dynamics (MD). In each
RMSD of the mean
case, the RMSD relative
structure (Å)6
to the starting model was
all backbone atoms (3-91)
0.609 ± 0.063
0.494
measured until the
all heavy atoms (3-91)
1.2128 ± 0.080
1.157
simulation was fully
equilibrated. The resulting models of wild-type and p.Arg4444Trp were then compared (Fig. 3D,
E). While the long flexible loop between residues 4468 and 4478 was significantly different
between these simulations, regions around the mutation were virtually unchanged in structure.
Thus, these in silico results are consistent with our CD work showing that the mutation does not
change the Ig59 structure significantly. Therefore, the p.Arg4444Trp variant likely directly alters
the obscurin-titin interface.
<20>

Best

The 20 ensemble structures, <20>, are the results of simulated annealing calculations. The best
structure is the closest to the average structure. The values shown for the <20> are the mean ±
standard deviation.
1

30

None of the 20 structures has a distance violation > 0.35 Å or a dihedral angle violation of > 5°.
The force constants used in the SA calculations are as follows: 1000 kcal mol −1 Å2 for bond
length, 500 kcal mol−1 rad−2 for angles and improper torsions, 4 kcal mol−1 Å−4 for the quartic van
der Waals (vdw) repulsion term (hard-sphere effective vdw set to 0.8 times their values in
CHARMm parameters), 50 kcal mole−1 Å−2 for experimental distance constraints, 1 kcal mol−1 Å−2
for distance symmetry constraints, 0.5 kcal mol−1 ppm−2 for the 13C chemical shift constraints,
and 1.0 for the conformational database potential. The force constants (in kcal Hz−2) used for
dipolar coupling restraints is 0.50.
3 Lennard-Jones van der Waals energies were calculated using CHARMm parameters and were not
used in any stage of the structure determination
4 Q-values were determined by randomly removing 10% of all RDC values. To ensure accuracy, an
ensemble of structures with a second randomly removed subset of RDCs was also run. The Q-value
of this second set was similar to the first.
5 PROCHECK was utilized to generate the Ramachandran plot
6 Backbone calculations include Cα, N, and C′ atoms. Only residues 3–91 are included since no
long-range NOE correlations were observed for residues 1–2 and 92–104.
2

The p.Arg4444Trp Variant Reduces the Interaction between Obscurin Ig58/59 and Titin Z9/Z10
Domains. To directly evaluate whether the p.Arg4444Trp variant alters the interaction of the
Ig58/59 domains of obscurin with the Z9/Z10 domains of titin, we performed GST-pull down
assays with either immobilized GST-obscurinWT or GST-obscurinMUT mixed with in vitrotranslated titin Z9/Z10, cloned in frame with a myc-tag epitope. Densitometric quantification of
the binding between the Z9/Z10 domains of titin and the Ig58/59 domains of obscurin showed
that the bound fraction of GST-obscurinWT protein was approximately two-fold higher than that
of the GST-obscurinMUT, indicating that the p.Arg4444Trp variant significantly weakens the
titin-obscurin interaction (Fig. 2D, 2E). Other groups have suggested that this titin-obscurin
interaction helps to strengthen the Z-line (Bang et al., 2001). Our results show that the
p.Arg4444Trp variant leads to a partial ablation of titin binding. This event leads to a weaker,
less organized cytoskeleton, which in turn contributes to the distal muscular dystrophy
phenotype of affected patients. This general mechanism of action is similar to the titin M10
mutations found in TMD and LGMD2J patients, which also serve to ablate a separate titinobscurin interaction.

Discussion
Based on the evidence that the M10 domain of titin is mutated in patients with TMD and
LGMD2J and that this domain interacts with the Ig1 domain of obscurin (Fukuzawa et al., 2008;
Pernigo et al., 2010), we hypothesized with our collaborators that the OBSCN gene could
represent a potential candidate for those cases of muscular dystrophies where a causative gene
had not been identified. Screening performed by our collaborators of families with undetermined
distal myopathy led to the identification of a novel variant in OBSCN, p.Arg4444Trp, which cosegregated with a c.5161delG in FLNC, in two individuals of a French family affected by distal
muscular dystrophy. The OBSCN p.Arg4444Trp variant is conserved across mammalian species
and is localized in a region of the protein that mediates the binding to the Z9/Z10 Ig domains of
titin which facilitates the localization of obscurin to the Z disk region of the sarcomere (Young et
al., 2001).
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Our structural studies showed that the previously mentioned variant does not lead to a
global Ig59 domain misfolding but instead changes the surface topology of the domain. This
mutation may thus affect obscurin binding to other members of the myofibril cytoskeleton. Pulldown experiments showed that this variant specifically weakens the binding between obscurin
and titin, which may contribute to altered sarcomere stability and, eventually, disease. In support
of this hypothesis, other mutations have been identified in patients with muscular dystrophies
that affect the titin-obscurin interaction. For instance, mutations in the titin M10 domain, which
mediates interaction with the Ig1 domain of obscurin at the M-band, were found to reduce the
affinity of titin for obscurin and cause gradual failure of sarcomere maintenance in muscles of
patients affected by TMD and LGMD2J (Fukuzawa et al., 2008; Pernigo et al., 2010). Similarly,
the p.Arg4344Gln variant located in the Ig58 domain of obscurin identified in a patient affected
by hypertrophic cardiomyopathy, was found to impair the binding of obscurin to the Z9/Z10 Ig
domains of titin (Arimura et al., 2007). Moreover, knock-in mice for the p.Arg4344Gln variant,
when exposed to stress via trans-aortic constriction, develop a severe cardiac hypertrophy within
4-8 weeks (Hu et al., 2016), further emphasizing the complementary roles of titin and obscurin in
maintenance of sarcomere stability.
Interestingly, the two variants of Ig58 and Ig59 mentioned in this text, p.Arg4444Trp of
Ig59 and p.Arg4344Gln of Ig58, involve a single point mutation from a charged to an uncharged
residue (Arimura et al., 2007; Fukuzawa et al., 2008; Guergueltcheva et al., 2011; Pernigo et al.,
2010). The isoelectric points of these regions are approximately 6.34 and 4.16, respectively.
However, the point mutations cause a shift in isoelectric point to 4.48 and 3.90, respectively.
Therefore, we hypothesize that the binding events between Ig58/59 of obscurin and Z9/10 of titin
is electrostatically driven and that the difference pIs account for the reduction in binding affinity
observed in the variants. In the future, we will test this hypothesis by creating a titin column and
testing its affinity for the obscurin wild types and variants. If a lower concentration of salt is
required to wash off the variant compared to the wild type, then we can effectively conclude that
the variant affinity is lowered due to a decrease in electrostatic interactions.
FLNC mutations are known to cause adult-onset distal muscular dystrophy (Kley et al.,
2012; Vorgerd et al., 2005; Shatunov et al., 2009; Luan et al., 2010). The protein product of
FLNC, filamin C, is an actin cross-linking protein involved in cytoskeleton organization and
signalling (Razinia et al., 2012). Mutations in FLNC were reported to destabilize muscle tissue
homeostasis via the formation of protein aggregates (Löwe et al., 2007). In addition, mutations in
FLNC have been detected in patients with myofibrillar myopathy and also in patients with hand
muscular dystrophy without myofibrillar aggregates (Duff et al., 2011; Guergueltcheva et al.,
2011).
Our collaborators’ clinical evaluations of the proband carrying both the OBSCN
p.Arg4444Trp variant and the FLNC deletion indicate a late-onset dominant distal muscle
dystrophy as well as the involvement of additional muscle groups than the Udd Myopathy (Duff
et al., 2011; Guergueltcheva et al., 2011). The FLNC mutation did not completely segregate with
the disease, as it was present in the two affected patients as well as one healthy individual in the
French family analyzed. This incomplete segregation matches the behavior of a similar FLNC
deletion reported in Bulgarian families (Guergueltcheva et al., 2011), indicating an incomplete
penetrance of the genotype. WES of representative individuals in the Bulgarian families did not
reveal the presence of any other gene variants shared by all patients. Thus, the genetics behind
the incomplete penetrance of the disease in the Bulgarian families remains unsolved and,
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therefore, needs further analysis. In the French family reported by our collaborators, the
combination of the FLNC c.5161delG frameshift and the OBSCN c.13330C>T variant cosegregated with the disease, with the OBSCN variant present only in the affected individuals. The
healthy relative presenting only the FLNC c.5161delG deletion can be regarded as partial
asymptomatic carrier.
In conclusion, the data on the French family reported by our collaborators depicts a novel
digenic heterozygosity condition in the genetics of distal dystrophy, resulting in a dominant
phenotype with quite severe clinical features; individual III:3 was unable to walk and constricted
to a wheelchair, and IV:2 was unable to run since the age of 16. This phenotype is caused
partially by an altered titin-obscurin interaction, and partially by altered filament C function of
unknown molecular etiology.
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Studies on the Molecular Motion, Structure, and Elasticity of Titin

Introduction
Titin’s ability to both stretch and recoil is fundamental in preventing muscle
overstretching and helps myocytes return to their original length. Recent studies have examined
titin’s mechanosensing abilities using tandem Ig and Fn-III-like domains (Granzier and Labiet,
2004; Linke et al., 2008; von Castelmur et al., 2008; Lee et al., 2010; Pernigo et al., 2010; Hsin
et al., 2011). While many of these domains are closely associated with other parts of the
cytoskeleton, there are ~100 tandem domains in the sarcomeric I-band that are relatively free
from extensive target protein interactions (reviewed in Kontrogianni-Konstantopoulos et al.,
2009). Improta et al. (1998) and von Castelmur et al. (2008) have shown that this I-band region
acts as a modified entropic spring whereby each domain behaves as a link in a chain connected
by 3-5 residue interdomain linker ‘hinges’ (Improta et al., 1998; von Castelmur et al., 2008)
(Fig. 1).
The further a
polypeptide is stretched,
the more energy
additional stretching
requires (Linke, 2000
(1);Linke, 2000 (2)).
Through extensive
molecular dynamics
(MD) simulations, Lee et
al. took this idea further
and developed a
comprehensive
mathematical model
where tandem Ig domains
behave as a kind of
entropic-enthalpic spring,
termed the ‘modified
Figure 1. Short linker regions of I6 between A) Ig66-67, B) Ig67-68, and
worm-like model’
C) Ig69-70.
(mWLM) (Lee et al.,
2007; Hsin et al., 2011). In this model, the Ig domains can move stochastically relative to one
another, though there is also some breaking and forming of transient domain-domain and
domain-linker non-covalent bonds. The mWLM agrees extremely well with the experimental
data and explains titin’s stretch resistance at very low forces (1-5 pN) (Linke, 2000 (1); Ma and
Wang, 2003; Hsin et al., 2011). At slightly higher forces (~5 pN), the mainly disordered PEVK,
N2A, and N2B regions of titin straighten out in an entropic-enthalpic spring mechanism
(Frieburg et al., 2000; Bang et al., 2001; Ma and Wang, 2001; Ma and Wang, 2003; Li et al.,
2002; Lee et al., 2007). At extremely high forces (>50 pN), discrete titin Ig and Fn-III domains
completely unfold, although the physiological relevance of such an event is uncertain (Rief et al.,
2000; Li et al., 2003; Garcia et al., 2009; Stacklies et al., 2009; Lee et al., 2010; Hsin et al.,
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2011). Thus, titin displays a continuum of soft elasticity with the application of force (Hsin et al.,
2011).
This nuanced view of titin’s flexibility at low forces runs somewhat counter to the crystal
structure of 6 tandem titin domains, I65-70 (I6), which depict well-formed interactions between
the linker regions and Ig domains (von Castelmur et al., 2008). Such fixed interdomain
interactions lead to the ‘carpenter’s ruler’ model. This model reconciles several incongruences
that arise from thinking of titin as a worm-like model: data collected by cryo-EM show large
segments of the I-band region to be in straight lines with only occasional bend points, and SAXS
data indicate a mostly elongated structure (Marino et al., 2006; Vazina et al., 2006; von
Castelmur et al., 2008; Marchetti et al., 2011). Additionally, the persistence length of the titin Iband region is longer than a worm-like model would suggest (Di Cola et al., 2005; von
Castelmur et al., 2008).
In an attempt to resolve the discrepancy between the worm-like and ‘carpenter’s ruler’
models, we re-analyzed the published crystal structure data (von Castelmur et al., 2008; Lee et
al., 2007). Many of the linker/domain interactions that are present in the original model and
contribute to an elongated overall structure are either absent or ambiguous in our structure (Fig.
1). Examination of symmetry mates suggest that the extended conformation of titin is not based
on stabilizing domain-linker interactions but based instead on crystal packing interactions.
Molecular dynamics simulations performed by others and ourselves support the theory
that this region of titin can be elongated, however the energy difference between a slightly bent
and a straight molecule are below the threshold of thermal noise (Lee et al., 2010). Together,
these X-ray and MD analyses structurally validate the mWLM. Titin likely forms transient
interdomain interactions, which explains the protein’s resistance to stretch and its persistence
length. These interactions, combined with limited flexibility due to steric hindrance between Ig
domains, serve to keep titin in a mostly elongated orientation. While there is computational and
circumstantial evidence for stabilizing interdomain interactions (Matsubara and Maruyama,
1977), their presence in this crystal structure is not definite.

Materials and Methods
Structure Refinement. PDB and reflection files from accession numbers 3B43 and 2RIK
were implemented in experimentation. The structure of 3B43 was refined computationally and
manually using PHENIX ver 1.72.2-869 and Coot was used for iterative rounds of structure
rebuilding and refinement in PHENIX refine (Terwilliger et al., 2008). Amino acids with
continuous, clearly defined electron density at 𝜎 ≥ 1.5 for at least two residues were included;
all others were excluded. Ramachandran outliers were identified using the Molprobity server and
Coot. Once identified, outliers were corrected. Refinement statistics are given in Table 1 (Chen
et al., 2010; Emsley et al., 2010). The 2RIK structure was used for investigation of crystal
packing interactions and the possible effects of packing on rigidity.
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Table 1. I6 statistics after refinement. Methods for data collection of I6 are found
in von Castelmur et al., 2008.

Molecular
Dynamics
Simulations. All
MD simulations
were performed
Solvent content (%)
with the PMEMD
Matthews coefficient
module of the
Amber 12 MD
Completeness (%)
software package,
Refinement:
the AMBER 12SB
No. of reflections
14953
force field, and a
No. of protein atoms in asymmetric unit
3371
generalized Born
R factor/R free (%)
28.4/31.0
implicit solvent
(Hornak et al.,
RMSD bond length (Å)
.0084
2006; Case et al.,
RMSD bond angle (°)
1.992
2012; Nguyen et al.,
Avg B factor (B factor range) (Å3)
88.5 (19.9-200.2)
2013). The nonWilson B factor (Å3)
82.6
bonded interaction
Ramachandran favored (%)
90.6
cutoff distances
Ramachandran outliers (%)
2.2
were set at 100 Å
for MD and 150 Å
for steered molecular dynamics (SMD). For equilibrium simulations, constant temperature (T =
300K) was enforced using a Langevin thermostat with a collision frequency of 1 ps-1. The
integration time step was 2 fs and all covalent bonds to hydrogen were held fixed with the
SHAKE algorithm.
Resolution range (Å)
Spacegroup
Unit cell dimensions

16.99-3.30
P6522
a=b=141.43Å, c=166.01Å
α=β=90°, γ=120°
67.1
3.74
98.6

Steered Molecular Dynamics Simulations. SMD simulations fixed the α-carbon at the Nterminus of Ig65 (A1) and applied force to the α-carbon at the C-terminus of Ig70 (Q567),
moving it closer to the N-terminus (Israleqitz et al., 2001). In this way the protein was
compressed at a constant velocity of 15 Å/ns. The SMD spring constant was set at 10 (kcal mol-1
Å-2).

Results
The original structure of I65-I70 is hook-shaped; the first two domains are oriented 114
degrees relative to the final four domains, which are nearly linear (von Castelmur et al., 2008).
The high B factors of the published structure prompted our re-analysis of the electron density in
3B43 to determine if the sections with high B-factors had well-defined electron density. A 1.5 σ
cutoff was used to fit the model in Coot. Continuous, unambiguous density for the backbone and
side chains was required; all other residues and side chains were removed (Table 1 for fitting
statistics and Fig. 2A). This newly refined structure has an RMSD of 0.6 Å compared to the
original with several important differences. The overall B-factor is significantly lower than the
original structure (88.4 Å3 vs 118.5 Å3; Fig. 2A inset). Furthermore, domain Ig68 is almost
completely absent. In our model, interactions between the Ig domains and linker residues, which
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were previously postulated to stabilize the structure in an elongated form, are either poorly
defined or absent (Fig. 2B). These residues were removed due to poor electron density (see
Materials and Methods for details). Analysis of the entire structure reveals a positive correlation
between extensive crystal packing interactions and low B-factors (Fig. 2A and C; Fig. 3).
From this
analysis, we
reasoned that the
overall shape of this
region of titin could
be explained by
crystal packing
interactions and not
through interprotein interactions
(Fig. 2D). Since
titin is predicted to
be moderately
flexible, this
hypothesis could
explain the
dichotomy between
MD simulations and
the crystal
structures. We
therefore
investigated the
structure of Ig6869-70 (2RIK),
which was
previously solved at
1.6 Å resolution to
determine if crystal
packing may have
also contributed to
Figure 2. A) Cartoon representation of Ig65-70, colored by B-factor. Inset is
its extended
the distribution of B-factors within the model. B) Linker region between Ig67
conformation (von
and Ig68, showing a lack of interactions and electron density to keep the
Castelmur et al.,
molecule rigid. C) Example of the extensive packing of Ig66 against its
symmetry mate, denoted with *. D) Global view of the crystal packing of Ig652008). As can be
Ig70 relative to symmetry mates. E) Global view of the crystal packing of the
seen in Fig. 2E,
2RIK structure with central molecule colored via B-factors (range from 20-65
this construct has
Å3).
extensive packing
interactions against its neighbors, and has correspondingly lower overall B-factors. Overlays of
the same domain in 2RIK and 3B43 show that, while the tertiary structure of the Ig domains are
virtually identical, the orientation of the Ig domains relative to each other vary (Fig. 4). We
conclude that the overall shape of I6 observed in the 3B43 crystal structure is most likely
dependent on crystal packing, not inter-protein domain-domain or domain-linker interactions.
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To examine
the flexibility of titin
Ig65-Ig70, we
performed a series
of MD and SMD
simulations on the
original titin
structure. Model
equilibration using
implicit solvent
conditions and the
AMBER ff12SB
force field showed
Figure 3. Crystal packing between A) Ig69 and B) Ig70 and their respective
that each domain
symmetry mates (denoted with *).
displayed significant
motions relative to
its neighbor over 10 ns (Fig. 5). This is despite the Ig domains themselves being essentially static
(average RMSD per domain over 10 ns is about 1.9 Å). This result agrees with similar
experiments performed by Lee et al. (Lee et al., 2010). To further probe the stiffness of this
section, we brought
together the two ends of
this structure together at a
rate of 15 Å/ns, from 232
Å to 141 Å. Analyses
show that the straight part
of the original structure
(Ig67-Ig70) bent readily
and that it required less
than 0.6 kcal/mol of work
(a rough cut-off for noise
attributable to random
thermal motion) to
Figure 4. Alignment of Ig68 between the 2RIK (cyan) and 3B43
decrease the end-to-end
(green) structure, showing that the neighboring Ig domains are in
distance to 200 Å (Fig.
different orientations between the two structures.
6A-C). Smaller-diameter
models required progressively more work. These data suggest that while the last 4 domains are
mobile relative to their neighbors, mobility only extends to roughly 140 degrees as measured
from the center of mass from each domain, in agreement with previous data (Lee et al., 2010). At
smaller angles, these Ig domains begin to run in to each other; thus, this molecule is intrinsically
partially elongated. These data agree well with previously published MD bending data, as well as
experimental SAXS data, showing that the average length of the I6 region is 220 Å (von
Castelmur et al., 2008; Lee et al., 2010).

38

Discussion

Figure 5. Snapshots of MD simulations for I6 at A) 2 ns, B) 5 ns,
and C) 9 ns of equilibration, showing the straightening and
bending of the final four domains. The models were aligned from
residue 98 to 288.

Here we re-analyze the Ig65Ig70 crystal structure and
suggest that the X-ray data do
not support the ‘carpenter’s
ruler' model of titin in solution.
Instead, these data agree with
subsequent MD simulations
showing that titin domains
move mostly independently of
each other, with only transient
inter-domain or domain-linker
interactions (Lee et al., 2010;
Hsin et al., 2011). This is
particularly evident in Ig68,
whose dynamic movement
makes it virtually invisible in
the structure. The presence of
motion in this region is likely
caused by a lack of symmetry
mates to pack against, resulting
in higher-than-average Bfactors.

Our new model of Ig65-70 does not explain EM data that indicate that this region of titin
is mostly elongated (von Castelmur et al., 2008). Several possibilities could explain this
discrepancy. First, it could be that transient interdomain and domain-linker interactions, while
weak, short-lived, and not present in the crystal structure, are present in sufficient quantities as to
exert a substantial stabilizing force on the molecule. These interactions could be overwhelmed by
thermal motion and crystal packing interactions and might not be seen in crystal structures. Such
interactions are built into the mWLM and seem to fit the wet lab stretching data (Lee et al., 2010;
Hsin et al., 2011). Previous SMD experiments had problems in explicit solvent with
hydrodynamic drag (Lee et al., 2010). Thus, another possible explanation is that titin, once
straight, tends to stay straight because of insurmountable solvent drag. Lastly, it may be that in
the conditions under which EM experiments were conducted, titin is particularly amenable to
forming straight lines.
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MD simulations argue for a
mWLM, yet previous a crystallography
structure suggest a more rigid molecule.
In this work, we identify crystal-packing
artifacts as contributing to the apparent
rigidity of the published crystal
structure. Thus, the crystallography data
in fact also suggest a dynamic system.
This more nuanced view of the X-ray
data reconciles this structure with the
subsequent MD simulations.

Figure 6. A) Force (in kcal/mol) v. distance (Å) graph
of Ig65-70 (PDB 3B43). Images of Ig65-70 at B) 0 and
C) 33 Å of compression.
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Insight into the Auto-inhibitory Mechanism of the Second Kinase Domain of Obscurin

Introduction
Obscurin isoform B is expressed in low levels in a wide variety of non-muscle tissues,
including epithelial, brain, liver, pancreas, and kidney tissues (Ackermann et al., 2014; Russell et
al., 2002; Stroka et al., 2016). This isoform of obscurin is unique in that it has two
serine/threonine kinase domains located near its C-terminus (Russell et al., 2002). Interestingly,
these kinase domains are the only direct signaling moieties in obscurin. Obscurin also contains a
RhoGEF/PH tandem domain that activates RhoA. All of these three obscurin regions— the two
kinase domains and the RhoGEF/PH tandem domain— are involved in cell adhesion and
signaling. The obscurin kinase domains phosphorylate cadherins while the activation of RhoA
causes downstream effects that influence integrin signaling (Hu and KontrogianniKonstantopoulos, 2013; Stroka et al., 2016). Ultimately, the cellular consequences of these
signals are increased cell adhesion and stress fiber formation.
Obscurin is normally associated with cytoskeleton stability and dynamics. Thus, these
three obscurin signaling domains provide a strong link between the cytoskeleton and cell
adhesion. Ablation of this link has considerable (but little-studied) physiological repercussions—
obscurin is the second-most mutated gene in breast and colorectal cancers (Wood et al., 2007;
Sjoblom et al., 2006; Stroka et al., 2016). Additionally, while non-tumorous tissue is rich in
obscurin, biopsies of human breast cancer tumors have shown that obscurin is nearly absent in
cancerous tissues (Stroka et al., 2016). Due to these findings, it is paramount to understand the
mechanism of action of these signaling domains and how mutations affect the activation,
expression, and/or functionality of obscurin.
The overall goal of this project is to obtain high-resolution crystal structures of both
human obscurin kinases, KI and KII. However, this goal has run into several significant hurdles.
KI does not express well. KII can be expressed, purified and crystallized, but this process is
extremely inefficient— protocols recovered an average of 1 mg from 16L of bacterial culture.
Therefore, in lieu of a crystal structure, we opted to model the KII domain using computer
simulations. Although the obscurin kinase domains have not been well-studied, the structure and
mechanism of activation of a similar kinase, the titin kinase, has been extensively studied
(Mayans et al., 1998; Mayans et al., 2013). Like all kinase domains, the titin and obscurin
kinases have two active sites that neighbor each other: a substrate binding site and an ATPbinding site. These sites
undergo cycles of activity and
inhibition, depending on the
needs of the cell, and as such,
have highly specific
regulatory and substrate
recognition mechanisms
Figure 1. Schematic showing the similarity between titin (left) and
(Mayans et al., 1998).
obscurin (right) kinase regions. All three kinases are preceded by
an Ig domain (green), the titin kinase and KI are also preceded by
an Fn-III domain (grey), and all three domains have an N-terminal
tail (NL, yellow) and C-terminal tail (CL) in obscurin or C-terminal
regulatory domain (CRD) in titin (red) (adapted after Hu and
Kontrogianno-Konstantopoulos, 2013).
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The titin and obscurin
kinases are serine/threonine
kinases; they phosphorylate

serine and threonine residues. The two domains have similar surrounding are modular and are
linked to the rest of the molecule through a (presumably) unstructured N-terminal and C-terminal
linkers (NL and CL, respectively) (Hu and Kontrogianno-Konstantopoulos, 2013; Mayans et al.,
2013) (Fig. 1). These domains are catalytically active; they can both auto-inhibit and autoactivate themselves (Mayans et al., 1998; Hu and Kontrogianno-Konstantopoulos, 2013) (Fig. 2).
This function is a hallmark of most kinases (Tsai and Nussinov, 2013).
In the context of the entire protein architecture, the obscurin domains mirror titin (Fig. 1).
Preceding the titin kinase are an Ig domain, an Fn-III (Fn-3) domain, and the N-terminal tail
(NL). Following the titin kinase are the C-terminal regulatory tail (CRD) and another Ig domain.
Similarly, in obscurin, the first kinase is preceded by an Ig domain and NL, followed by the CL.
The second kinase domain region is also similar in its organization; as it is preceded by an Ig
domain, Fn-III domain, and NL, and immediately followed by its CL (Fig. 1). The CL is at the
extreme C-terminus of obscurin and, therefore, there is no possibility of an Ig domain following
the CL.

Figure 2. Gel depicting the auto-phosphorylating nature of
obscurin KII as well as its ability to phosphorylate cadherins
(taken from Hu and Kontrogianni-Konstantopoulos, 2013).

The titin kinase
is usually inactive; structural
studies have shown that the
CRD wraps around the kinase
domain and occludes the ATPbinding pocket. In addition, the
N-terminal region of the titin
kinase can also bind at or near
the active site. Together, these
domains prevent ATP-binding.
(Hu et al, 1994; Kobe et al.,
1996; Mayans et al., 1998;
Gold et al., 2006) (Fig. 3).

The titin kinase
domain’s unusual autoinhibitory structure hints at its
mechanism of action. Titin
acts like a molecular spring;
when stretched, the
mechanical stretch physically
removes the NL and CRD
from the titin active site,
freeing it for substrate- and
ATP-binding (Grater et al.,
2005; Puchner et al., 2008;
Figure 3. Lateral and frontal surface views of titin kinase showing
Puchner and Gaub, 2010;
the inhibited conformation. Note the position of the NL (yellow)
Stahl et al., 2011). The NL
and CRD (red) in relation to the active site, Δ (taken from Mayans
and CRD binding each
et al., 2013).
effectively halves the catalytic
activity and, therefore, the phosphorylation levels of the titin kinase. Together, the NL and CRD
silence phosphorylation levels completely (Johnson et al., 2001; Masterona et al., 2011). This
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mechanism is the only known mechanism of how the cytoskeleton directly acts as a
mechanosensor- titin stretch results in target phosphorylation through the release of this autoinhibitory mechanism.
Given that obscurin and titin have a similar overall architecture, perform similar
connecting functions within the cytoskeleton, and contain similar kinase domains, we
hypothesize that the kinase domains also are stretch-activated mechanosensors. As a first step to
testing this hypothesis, we must determine whether the NL and CL regions of the obscurin kinase
domains interact with the kinase domains. Towards this beginning goal, we took a two-pronged
approach. To further investigate the auto-inhibitory mechanism of KII, the recombinant domain
was purified and crystallized. From these crystals, the high-resolution crystal structure KII will
be solved, though work is still in progress. Parallel to this wet-lab work, we also study computer
simulations of KII. Herein, I describe the binding affinity studies performed on a simulated
model of KII obtained by using titin’s kinase as a model structure. The data indicate that,
although the N-terminal tail of KII cannot bind to the active, site, the C-terminal domain appears
to bind.

Materials and Methods
Purification of Obscurin KII. Protein samples derived from a pet-24a(+) construct containing a
codon-optimized human obscurin KII domain were expressed in E. coli and purified as follows:
Starter cultures (~5mL) of KII were made following addition of glycerol stock (500 μl KII
pET24a BL-21 cells into 50/50 glycerol) and 10 μl of kanamycin. Starter cultures were shaken
overnight at 37°C, 250 rpm, then added to 1 L flasks of LB (10 g tryptone, 5 g yeast extract, 5 g
NaCl, in 1L dH2O), along with 1 mL kanamycin. These flasks were shaken at 37°C, 250 rpm.
Induction occurred ~3 hours later, at 0.6-0.8 OD600, with the addition of 0.2 g isopropyl β-D-1thiogalactopyranoside (IPTG). Approximately 3 hours later, flasks were taken out of the
incubator/shakers and centrifuged using a JLA 16.250 rotor at 6000 rpm, 4°C for 15 min. The
supernatant and pellet were separated and the pellet was kept at -80°C until ready for further
purification. Pellets were resuspended in His-tag binding buffer ((50 mM NaH2PO4, pH 8.0, 0.3
M NaCl, 100mM imidazole)) and 100 μl phenylmethane sulfonyl fluoride or
phenylmethylsulfonyl fluoride (PMSF) was added to prevent degradation during sonication at
100% amplification, 15 s pulse, for 30 min, then centrifuged using a JA 25.50 rotor at 14000
rpm, 4°C, for 30 min. The resulting pellet underwent two cycles of 8 M urea resuspension and
centrifugation under the same conditions as described previously. PMSF (100 μl) was added to
the resulting supernatant, which was then dialyzed in a buffer containing 50 mM NaCl and 20
mM Tris pH 7.5 at 4°C for 2-3 hours. This solution was centrifuged again using a JA 25.50 rotor
at 14000 rpm, 4°C for 30 min, then the supernatant was run over a Nickel column. The eluent
was concentrated in a 5K concentrator tube via centrifugation at 4500 rpm, 4°C for 90 min
intervals until less than 1 mL solution remained, then run over a size exclusion column. Contents
of column fractions were visualized using gel electrophoresis; fractions containing KII were
pooled and concentrated. The concentration of KII in the resulting solution was obtained using a
Thermo Scientific Nanodrop 2000 Spectrophotometer using the extinction coefficient (42330
cm-1mol-1) and molecular weight (30.3 kDa) of KII.
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Crystallization. The hanging drop method with various crystallizing solutions was used to obtain
KII crystals. Crystals were harvested and frozen in liquid nitrogen until X-ray diffraction
analysis using a glucose cryoprotectant.
Model Creation and Verification. The sequence of KII was modeled using PHYRE homology
modeling. Verification of the model was performed in YASARA under explicit solvent
conditions for ~15 ns (Krieger et al., 2014; Krieger et al., 2004). The N-terminal and C-terminal
tails were not modeled using PHYRE as they were predicted to be relatively unstructured
regions.

Figure 4. Sequence of KII showing active residues (magenta), NL (yellow), and CL (red).
Sequence of KII obtained from PubMed obscurin isoform B, where numbers to the left indicate the
residue number in the obscurin isoform.

Active Site Determination. Active residues in KII were determined via COACH analysis
protein/ligand binding site prediction meta-server (Yang et al., 2013) (Fig. 4).
N-terminal Binding Affinity Tests. The NL was modeled by hand as a random coil in YASARA
and allowed to equilibrate for ~10 ns (Krieger et al., 2014; Krieger et al., 2004). The N-terminal
tail and KII domain were the run through HADDOCK2.2 web docking prediction interface
server (van Zundert et al., 2016). Ligand 1 was KII, with active residues as predicted by COACH
and ligand 2 was the N-terminal tail.
C-terminal Binding Affinity Tests. The CL of KII was modeled by taking the PHYRE model and
fusing it to the C-terminal regulatory domain of titin. The titin sequence was then swapped out
and replaced with the obscurin KII sequence. The CL and KII domain were the run through
HADDOCK2.2 web docking prediction interface server (van Zundert et al., 2016). Ligand 1 was
KII, with active residues as predicted by COACH. Ligand 2 was the CL. Five runs were run in
total with each run marking a different active segment of the CL. Runs were structured to run 10
CL residues as active with each sequential run overlapping by four residues. For the purposes of
these tests, only the first 26 residues of the CL were tested; the CL wraps almost entirely around
the main chain of KII and it would be nearly impossible for the residues directly behind the
catalytic core to bind.

44

Results
The obscurin KII model was made using the PHYRE homology program with the titin
kinase as a template (Fig. 5A). The original PHYRE-based model is seen in Fig. 5B. To verify
the stability of this model, the model was equilibrated for 15 ns in explicit solvent at 310K using
YASARA. At this point, no
significant conformation
changes were observed and the
ATP-binding pocket remained
intact (Fig. 6). The average
structure and last structure,
shown overlaid in Figure 5,
have an RMSD of 1.436.
Therefore, this equilibrated
model was deemed of
sufficient quality to move
forward with binding affinity
Figure 5. A) Cartoon representation of titin kinase showing the
simulations.
(yellow), CRD (red), and active residues (taken from PDB). B)
Model of KII showing active residues (magenta), CL (red), and NL
(yellow).

Following structure
validation, the N-terminal tail
was modeled by hand using the add residue function in YASARA. This procedure was chosen
due to the small size of the NL; it is only 20 residues and is not predicted to have any regular
secondary structure. Therefore, a random coil, allowed to equilibrate in solution, was a good
starting point for initial binding studies. The NL and
KII were then sent through a HADDOCK prediction
binding web server to determine the likelihood of
binding between the N-terminal tail and the active site
of KII. HADDOCK is an information-driven flexible
docking approach that predicts binding energies from
predicted protein interfaces using ambiguous
interaction restraints. Thus, this is an off-shoot of other
ab initio binding algorithms. As an output,
HADDOCK primarily uses a Z-score. This number
represents the separation from the mean of all clusters
Figure 6. Average (green) and last (cyan) tested. Thus, the lower the Z-score, the better a certain
structures obtained from the YASARA
target docks into the protein binding site, as measured
verification of the KII model during ~15 ns against a random insertion event (van Zundert et al.,
of equilibration in explicit solvent.
2016).
While the RMSD for NL binding to KII is large, the overall Z-score is moderately good,
suggesting that the NL can bind to the kinase domain. However, close examination of the
structure reveal that these models require the removal of a critical beta strand in the kinase
domain in order to bind. Given that this strand is a central part of the kinase domain, we suspect
that this binding event would not occur in reality. HADDOCK runs with this beta strand intact
demonstrate poor binding. (Fig. 7A-C). Similar results were obtained with an increased size in
the KII binding pocket, indicating that even a large binding area did not improve NL binding. In
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total, these data strongly suggest that, despite its close proximity, the N-terminus does not
substantially interact with the KII active site (Fig. 7A-C).

Figure 7. A) Model of KII (cyan) with all β-strands intact. The NL not shown to
more clearly see all five β-strands. B) Model of KII (cyan) and NL (yellow)
after the fifth β-strand was removed. C) HADDOCK results of Z-score vs
RMSD showing large, variable RMSD between the two structures. The
structure shown in B is Cluster 23, displayed by black triangles in the plot.

Figure 8. A) Model of KII (cyan) and C-terminal tail (red). B) HADDOCK
results for the test of KII ATP-binding site with residues 4-14 of the CL
showing Z-score vs RMSD showing small, stable RMSD between the two
structures. The structure shown in A is Cluster 2, displayed by blue triangles in
the plot.
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Although the
N-terminal tail
could not bind to
KII’s active site,
this would not
necessarily be the
case for the CL.
This tail is longer
than the N-terminus
at 44 residues. This
long region
precluded modeling
by hand. Since this
tail may act similar
to the titin domain,
the CL sequence
was threaded
through the titin
CRD Structure. As
the CL begins on
the opposite side of
the molecule from
the active site, only
the end of this
stretch was tested.
Proximal residues
would be to far
away to bind to the
active site.
We tested
this binding in two
ways. First, we
threaded the
obscurin Cterminal domain
through the titin
CRD region and
docked this onto
our obscurin KII
model. We then let
this region
equilibrate in
explicit solvent

using YASARA for 50 ns. Analysis from this simulation indicated multiple regions of the
obscurin CL could bind to our KII model. Next, we took overlapping sequences of the KII CL
and performed HADDOCK runs into the KII active site, in a similar way to how we tested the Nterminal region. In total, 5 separate KII/CL runs were completed, each considering 9 possible
clusters. Consecutive runs differed in the ‘active’ region of the CL, beginning with the first ten
residues and overlapping by 4 residues each time. In other words, residues 1-10, 4-14, 8-18, 1222, and 16-26 were run separately. HADDOCK results consistently predicted binding between
the CL and KII’s active site with low RMSDs and reasonable Z-scores (generally >-1.7) (Fig. 8).
The run in Figure 8 considered the ATP-binding site and residues 4-14 of the CL as active and
shows cluster 2 from the 4-14 run. The interactions between the NL and active site tended to be
electrostatic interactions.

Discussion
HADDOCK analysis determined that the NL was able to bind to the active site of KII but
only if there was significant displacement of the fifth β-strand, which is unlikely due to the
extensive hydrogen-bonding amongst β-sheets. Binding occurred via electrostatic interactions
between the KII active site and NL when this fifth β-strand was removed. Consistent binding was
observed between the CL and the active site, as shown by HADDOCK analysis. This binding
occurred electrostatically between the ATP-binding site of KII and the CL and is presumably
similar in nature to that of the CRD binding to the ATP-binding site of the titin kinase. However,
the in vivo and in vitro validity of the obscurin KII/CL binding event has yet to be tested. If the
binding is relatively strong, then it is likely that the CL has some inhibitory nature on the active
site. If not, then KII must be auto-activated and auto-inhibited by some other mechanism. Given
that not all proteins in the titin-like family are activated in the same manner as each other, nor as
titin itself (Mayans et al., 2013; Greene et al., 2008), coupled with our findings regarding the NL
and KII, this possibility may be even more likely as the possibility that obscurin and titin kinases
hold similar mechanisms of activation.
In the future, we hope to quantify the strength of the KII/CL binding using YASARA to
determine how much force is required to break the electrostatic bond between the two structures.
To complement this computer research with wet-lab work, we will design and implement an
affinity column to test the affinity of the CL for the kinase domain as well as the ability of the
CL to displace substrate and/or ATP from the active site(s) of KII. Lastly, we will continue to
crystallize KII in order to solve its crystal structure.
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Appendix A: Methods for Additional Projects

Materials and Methods (KI)
Purification of Obscurin KI. Protein samples of pet-24a(+) human obscurin KI were expressed in
E. coli and purified through the following procedure. Pet-24a(+) KI was transformed onto BL-21
cells and starter cultures (~5mL) of KI were made from these with the addition of 10ul of
kanamycin. Starter cultures were shaken overnight at 37C, 250rpm, then added to 1L flasks of
LB (10g tryptone, 5g yeast extract, 5g NaCl, dilute to volume with diH2O), along with 1mL
kanamycin. These flasks were also shaken at 37C, 250rpm. Induction occurred ~3hr later, at 0.60.8 OD, with the addition of 0.2g IPTG. Approximately 3hr later, flasks were taken out of the
incubator/shakers and centrifuged using a JLA 16.250 rotor at 6000rpm, 4C for 15min. The
supernatant and pellet were separated and the pellet was kept at -80C until ready for further
purification. Pellets were resuspended in G75 buffer (20 mM Tris pH 7.5, 50 mM NaCl, diH2O),
100ul PMSF was added to prevent degradation during sonication at 100% amplification, 15s
pulse, for 30min, then centrifuged using a JA 25.50 rotor at 14000rpm, 4C for 30min. The
resulting pellet was resuspended in 8M urea and centrifuged under the same conditions as
described previously. PMSF (100ul) was added to the resulting supernatant, which underwent
fast dialysis 20mL of G75 buffer at (4°C). This solution was centrifuged again using a JA 25.50
rotor at 14000rpm, 4C for 5min, then the supernatant was run over a Nickel column. All
fractions of the Nickel column were visualized using gel electrophoresis.

Materials and Methods (Rho-GEF)
Purification of Obscurin Rho-GEF. Protein samples of pet-24a(+) human obscurin Rho-GEF
were expressed in E. coli and purified through the following procedure. Pet-24a(+) Rho-GEF
was transformed onto BL-21 cells and starter cultures (~5mL) of Rho-GEF were made from
these with the addition of 10ul of kanamycin. Starter cultures were shaken overnight at 37C,
250rpm, then added to 1L flasks of LB (10g tryptone, 5g yeast extract, 5g NaCl, dilute to volume
with diH2O), along with 1mL kanamycin. These flasks were also shaken at 37C, 250rpm.
Induction occurred ~3hr later, at 0.6-0.8 OD, with the addition of 0.2g IPTG. Approximately 3hr
later, flasks were taken out of the incubator/shakers and centrifuged using a JLA 16.250 rotor at
6000rpm, 4C for 15min. The supernatant and pellet were separated and the pellet was kept at 80C until ready for further purification. Pellets were resuspended in His-tag binding buffer
((500mM NaH2PO4, pH 8.0, 3M NaCl, 100mM imidazole for 10x)) and 100ul PMSF was added
to prevent degradation during sonication at 100% amplification, 15s pulse, for 30min. Then the
solution was centrifuged using a JA 25.50 rotor at 14000rpm, 4C for 30min and the supernatant
was run over a Nickel column followed by a DEAE column. The eluent from the DEAE column
was visualized using gel electrophoresis and then concentrated in a 5K concentrator tube via
centrifugation at 4500rpm for 90min intervals until less than 1mL solution remained.
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Materials and Methods (Rho-GEF-PH)
Purification of Obscurin Rho-GEF-PH. Protein samples of pet-24a(+) human obscurin RhoGEF-PHwere expressed in E. coli and purified through the following procedure. Pet-24a(+) RhoGEF-PH was transformed onto BL-21 cells and starter cultures (~5mL) of Rho-GEF-PH were
made from these with the addition of 10ul of kanamycin. Starter cultures were shaken overnight
at 37C, 250rpm, then added to 1L flasks of LB (10g tryptone, 5g yeast extract, 5g NaCl, dilute to
volume with diH2O), along with 1mL kanamycin. These flasks were also shaken at 37C, 250rpm.
Induction occurred ~3hr later, at 0.6-0.8 OD, with the addition of 0.2g IPTG. Approximately 3hr
later, flasks were taken out of the incubator/shakers and centrifuged using a JLA 16.250 rotor at
6000rpm, 4C for 15min. The supernatant and pellet were separated and the pellet was kept at 80C until ready for further purification. Pellets were resuspended in His-tag binding buffer
((500mM NaH2PO4, pH 8.0, 3M NaCl, 100mM imidazole for 10x)) and 100ul PMSF was added
to prevent degradation during sonication at 100% amplification, 15s pulse, for 30min. Then the
solution was centrifuged using a JA 25.50 rotor at 14000rpm, 4C for 30min and the supernatant
was run over a Nickel column followed by a DEAE column. The eluent from the DEAE column
was visualized using gel electrophoresis and then concentrated in a 5K concentrator tube via
centrifugation at 4500rpm for 90min intervals until less than 1mL solution remained.
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Appendix B: Tutorial on How to Solve a Crystal Structure using HKL2000, Phenix, and
Coot
HKL Steps:
Step 0: Open HKL2000
Open a terminal window, go all the way up in directories. Then go through ‘usr’ to ‘local’ to
‘bin’ and open HKL2000. To do this type:
cd ..
cd ..
cd usr
cd local
cd bin
hkl2000
Step 1: Load Data
Once HKL2000 has opened fully, look under the space titled ‘directory tree’ and click on
‘berndsce,’ ‘Desktop,’ ‘APS4102014,’ then on the data folder you will be working on (eg.
‘JMU113’ or ‘JMU211’).
Designate your input folder, which is the data folder you just chose. This is where HKL will scan
for data files. Create or assign where the output files will go and click ‘load data sets.’ To create
a new folder, click ‘Create Directory’ and type the name.
Click ‘Load Data Sets.’ You will choose the file with ‘data’ in the name, and NOT with ‘scan’ in
the name. Once this has opened, record your wavelength and frame width. Then, click on the tab
entitled ‘Index.’
If there is more than one data set, you will have to do run HKL twice, once with each data set.
DO NOT try to do one HKL using both data sets. You can merge them later in CCP4.
Step 2: Indexing
Click on ‘fit basic’ and make sure that there are exactly 6 red boxes. Set resolution maximum to
‘corner’ if you think there is data that was not included and to ‘edge’ if you only want to go to
the user set boundaries of the original data. For Synchrotron data, ‘corner’ is more appropriate.
The minimum resolution should be 50.00. Click on ‘Peak Search,’ then, in the new window that
appears, click on ‘Peak Sear,’ and minimize the random peaks. This will usually involve
lessening your peaks until they fall within the range 300-800. Record the number of peaks. Once
this is done, click ‘OK’ then ‘Index.’
Step 3: Choosing a Space Group
When the window appears for you to choose a space group, choose the group that has the highest
symmetry with the lowest percent (usually it is green and closest to the top). Then click ‘Apply
and Close.’
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Step 4: Refining
Your χ2 values should be less than 2. Click ‘Refine’ and continue to refine until your χ2 values
level out (are constant). At this time, the ‘Integrate’ button should be green (ideally). If it is,
press it.
If not, click ‘Fit All’ then ‘Refine’ again until the χ2 values level out. You may also need to
change you space group, the values of which will have change due to your refining. Click
‘Bravais Lattice’ to open up your space group options. Again, choose the one with the most
symmetry. If you do change your space group, you will need to refine again. Record the space
group at the top of this screen. ‘Integrate’ should be green now, so press it.
Step 5: Integrate
Your mosaicity value should be less than 1. Record both it and your resolution range. Ideally, the
graph on the left should look like one downward slope while the graph on the right should be
fairly constant. Record your positional, partiality, X- χ2, Y- χ2, and χ2 values.
Step 6: Scale
Click on the ‘Scale’ tab at the top and make sure your space group matches with the one you
previously chose. Make sure that the box next to ‘Small Slippage, Imperfect Goniostat’ is red.
Click ‘Fix B’ and make sure that ‘Write Rejection File’ is red also. Then click ‘Scale Sets,’
which should be green.
Pay close attention to the graphs titled Completeness vs. Resolution and I/Sigma and CC1/2 vs.
Resolution. These will aid you in determining the minimum value of your resolution. On the
Completeness vs. Resolution graph, move your cursor to where the blue line begins to drop and
remember this number. Scroll down to the CC1/2 vs. Resolution graph and move your cursor
along the grey limit to where the grey meets the blue. This number should match up fairly
decently with the number from before. However, to be more accurate, click on the ‘Show Log
File’ button at the bottom and scroll down on the window that opens to the bottom. Compare the
values in the Average I column to those in the Average error column and record the Shell lower
limit for the line in which the Average I is approximately 2 times that of the Average error. This
will be the minimum value of your resolution. Hit ‘Close’ on this window when done, set your
minimum resolution, and the maximum for 50.
Click ‘Delete Rejection File’ then ‘Scale Sets.’
Record a, b, c and alpha, beta, gamma.
Your output file will have the name output.sca and will be wherever you specified it to go in the
‘Data’ tab. This is what you will use in CCP4.
CCP4 Steps:
Step 0: Opening CCP4
From the Finder, go to ‘Applications,’ then ‘ccp4-6.4.0’ and ‘ccp4.’ (If it is not already down on
the tabs, which it should be)
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Step 1: Running CCP4
On the right side of the screen there is a program list. Under ‘Data Reduction and Analysis,’
click ‘Symmetry, Scale, and Merge (Aimless).’
In the window that pops up, make sure that ‘Option to skip scaling & just merge’ is black. Also,
make sure the FreeR column has 0.05 in the blank and that ‘Copy FreeR from another file’ is
grey. Change the Input reflection file type to ‘Scalepack file’ and choose your input/output
destinations. SCA #1 is your input. You must input the ‘output.sca’ file, NOT the ‘scalepack.sca’
file.
HKLOUT is where you type/choose the output destination. When choosing your output
destination, you will have to name the file. To do this, choose the folder destination, click ‘OK’
and then add to the blank a /_____.mtz where the ____ is the desired file name. Then click ‘Run’
and ‘Run Now.’
If the process is finished quickly, chances are that you did something wrong. It should at least
take a few seconds.
Phenix Steps:
Step 0: Opening Phenix
Go to the ‘Finder’ icon and click ‘Applications,’ ‘Phenix 1.8.4.’ This will open the Phenix Home
window.
Step 1: Select Project
You will need to create a new project file that will store your data. On the Phenix Home screen,
click ‘New project,’ then give the project an ID and a directory. There can only be one project
per directory, so you may need to create a new folder in Finder that will become your directory.
When done, click ‘OK’ and make sure there is a green check by your new project ID. If there
isn’t one, double click on the ID.
Step 2: Xtriage
On the right side of the Phenix Home screen, look under ‘Reflection tools,’ and click on
‘Xtriage.’ In the bar next to ‘Reflections,’ you will browse to find the .mtz file you created in
CCP4. Then click ‘Run.’
In the new tab, there will be a subtab called ‘Twinning analysis.’ Click this and scroll down to
‘Likely point groups.’ Choose your point group and record it in your lab notebook. Then, save
the file with a file name as ____reindexed.mtz where ___ is the desired name of the file. MAKE
SURE TO ADD THE .mtz TO THE END.
Step 3: Molecular Replacement
Back at the Phenix Home window, under ‘Molecular replacement,’ click on ‘Phaser-MR (simple
interface).’ Add your reindexed file by clicking ‘Add file.’ It should be in a folder labeled
Xtriage. This will be your X-ray data file.
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Put 95 in the ‘Sequence identities’ bar then look under
‘Search options.’ Here, change ‘Also try alternative space group(s)’ to ‘All possible in same
point group.’
You will also need to add a .pdb file, which will be your input model. Click ‘Run’ and ‘Run
locally.’ When Phenix has finished, click ‘Run phenix.refine.’
Step 4: Refining
In ‘Refinement settings,’ make sure the following are checked: ‘XYZ coordinates,’ ‘Real-space,’
‘Rigid body,’ ‘Individual B-factors,’ ‘Automatically correct N/Q/H errors.’ All else should be
left unchecked.
If this is your first time refining, under ‘Input data’ go to Options…’ and make sure that
‘Generate new R-free flags’ is checked. Also, change ‘Fraction of reflections in test set’ is .05.
If this is your second time refining, you should check ‘TLS parameters,’ ‘Simulated annealing
(Cartesian),’ and ‘Simulated annealing (Torsion angles)’ under the ‘Refinement settings’ tab.
You will also need to go back to ‘Options…’ and uncheck ‘Generate new R-free flags.’ Also,
you will replace the .mtz file from Xtriage and instead use the file ending in ____data.mtz as
your new X-ray data file.
Once you have refined significantly, you may want to do the following...
Uncheck ‘Rigid body,’ which will rotate your structure within the electron density. Do
this if you find that, when refining, the computer flips or turns you structure in a way you don’t
want it to.
Check ‘Optimize X-ray/stereochemistry weight’ and ‘Optimize X-ray/ADP weight,’
which will have the program put more emphasis on the data you already have.
Uncheck both ‘Simmulated annealing…’ once your loops are in good shape, as this part
checks your loops.
Check ‘Update waters’ to put in waters to your structure. ONLY do this when your
structure is as good as you can get it (or near so). In other words, only towards the end of
refinement.
Once you think you are done, record the refinement number and the Rfree value for that
refinement.
COOT Steps:
The figure below shows the electron density map for the protein. You need to make the sequence
fit into the blue or green parts of the map. To do this follow the steps provide below.

Step 0: Opening a Structure in Coot
Click on ‘Open Coords…’ and select the .pdb file you received in the above steps. It will
probably either be in an Xtriage folder or a Refine folder. You can also do this by clicking on
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‘File’ then ‘Open Coordinates’ and selecting your .pdb file. This will open the chain of amino
acids.

You will then need to open up the electron density map. To do this, click on ‘File,’ then ‘Auto
Open .mtz’ and select the .mtz file that does NOT contain data in the name.
Go to ‘Draw,’ then ‘Cell and Symmetry,’ ‘Yes,’ ‘Show,’ and ‘Apply’ to show the unit cells.
Step 1: Basic Coot
Right clicking and scrolling will allow you to zoom in and out of your structure.
Left scrolling will allow you to change how much electron density it shown. The numerical value
will be displayed at the top of the structure picture. You should operate within the 1.5-2 range of
these values.
Left clicking on an amino acid will label it. To remove labels, go to ‘Measures,’ ‘Distances and
Angles’ and click ‘Clear All Atom Labels.’
Left clicking and dragging will allow you to rotate the x-, y-, and z-axes around the center of
your screen, which is represented by a pink square in the center of Coot.
Holding down the control button on your keyboard while left clicking and dragging will allow
you to move the center of your screen.
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When you are manually fitting the sequence into the density map, you want to get the sequence
into the blue or green density as shown above. When there is red density, this means that the
sequence is not favorable to be in that area. You want to AVOID the red density*. The blue
density is the occupied area that is acceptable.
*When there is red density within your blue density, to use Dr. Berndsen’s words, “cry.” There is
not much you can do here except use the ‘Real Space Refine Zone’ feature to move it out of the
way as best as possible. This feature will auto fit your amino acid to the electron density map.
Step 2: Navigating the Structure

To move from amino acid to amino acid, select the ‘Go To Atom’ under the ‘Draw’ pulldown
menu. This will allow you to move throughout the sequence one amino acid to the next. If there
is more than one chain, it may be necessary to designate which one you want to navigate
through.

The ‘Go To Atom’ screen looks like the figure above. You can move forward in the chain by
clicking “Next Residue”. To move backward click on “Previous Residue.”
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An easier way to do this is to go to ‘Draw’ then ‘Sequence View’ and your .pdb file. This will
display the entire chain in a window. Moving this window to the side will allow a quick jump
from amino acid to amino acid. Clicking on the desired amino acid number will place you at that
spot.

Step 3: Real Space Refine Zone
The ‘Real Space Refine Zone’ may be the most helpful tool that Coot has to fit your structure.
This will fit your amino acid to the electron density and allow you to position it the way you
want.
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The ‘Real Space Refine Zone’ will auto fit an area that you select. This will get the angles and
bonds in optimal orientations for the sequence. To select one amino acid to refine, double click
on some part of the amino acid. To select a larger region, single click on each side of the region. .
Dragging an amino acid or region will allow you to finagle the region where you want it. It is
easiest to grab the region by clicking and dragging from a “corner” or “bend” of the region. You
will then have to accept or reject the refinement. Ideally, all of the categories below will be
green.

Once the bonds and angles are in the optimal orientation press the accept button to keep the
changes you made on the structure. Use discretion to determine whether or not an orientation is
suitable. It is more important to match an amino acid to the given electron density than it is to
have the orientation be optimal (have everything be green).
There will be many green and blue regions surrounding the atom where waters, calcium, etc. will
eventually go. Do not panic if you see these seemingly random regions go unfilled.
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‘Regularize Zone’ is similar to ‘Real Space Refine Zone’ but may make more drastic changes. If
you are having a lot of difficulty with a region, this may be good place to go as more of a last
resort and may point you in the right direction.
Step 4: Mutate and Auto Fit
If you want to change an amino acid, use the ‘Mutate & Auto Fit’ button from the side menu that
is shown above then select the amino acid you want to change it to. This can also be done with
the ‘Simple Mutate…’ feature, but this will not fit the amino acid to your electron density.
Step 5: Add Terminal Residue
If there is an amino acid missing from the sequence you can add in an amino acid by using the
‘Add Terminal Residue’ button. After clicking it, click on the terminal carbon of your structure
and then on ‘Accept’ in the window that pops up. Make sure that the added amino acid (it will be
faded grey) is inside the electron density on your screen (you can move it by clicking on the grey
amino acid and dragging it) before hitting ‘Accept.’
If the amino acid appears and is not connected to the rest of your chain, simply click ‘Real Space
Refine Zone’ and select an area containing the terminal residue and the newly added amino acid.
The amino acid should then connect.
Step 6: Ramachandran Plots
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To view the Ramachandran Plot, go to Validate, then Ramachandran Plot, then click on the .pdb
file that you would like to view in the Ramachandran plot. You need to check the Ramachandran
plot before you run the comprehensive validation because to have a good structure meaning that
all the amino acids are in the pink regions on the Ramachandran plot.

As shown in the Ramachandran plot, all the residues need to be in the pink regions (ideally). If
they are not you need to move the residue into the pink region, or at least the yellow region.
When hovering your mouse over a square or triangle, it will show which amino acid that shape
relates to. Those amino acids with squares have different Ramachandran favored regions than
those with triangles.
For a structure to be considered good, you need to have zero “Ramachandran outliers” and
minimal “in allowed regions” (maximum in “favored” regions). Once you have checked this plot
than you can go forward with validating your structure.
A red shape means that the amino acid is a Ramachandran outlier, and should be fixed. A blue
shape means that the amino acid is not an outlier, although it may or may not be in the favored
region. A green shape represents the amino acid you currently have your screen’s focus on. Note
that fixing an amino acid may involve moving the amino acids immediately before and after it.
To fix or move an amino acid’s configuration, you can use the ‘Real Space Refine Zone,’
‘Regularize Zone,’ or ‘Edit Backbone Torsions.’ All of these can be found on the right side of
the Coot window, and ‘Edit Backbone Torsions’ may be the most helpful.
Step 7: Edit Backbone Torsions
Once in the ‘Edit Backbone Torsions’ window, you can either rotate from the peptide or the
carbonyl. Note that this will change the Ramachandran plot for both the amino acid you are
rotating and the one(s) around it. Try to get both shapes in the desired pink region, but make sure
that they stay within the electron density.
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Step…: Check/Delete Waters
When you have refined a structure using the ‘Update Waters’ feature in the refinement settings,
the program will place waters in spots they do not actually belong. One way to check whether or
not these are likely water spaces, click on ‘Validate,’ then on ‘Check/Delete Waters’ and ‘OK.’
This will bring up a small window in which questionable waters are displayed. Check to see if
the waters in these spots are too close or have too small of an electron density to constitute true
waters. Note that there may be more incorrect waters than those in the questionable water
window and that not all of the questionable waters may be incorrect. Use your best abilities to
discern whether or not there should be waters in each place.
Back to Phenix: Generating Table 1
Step 0: Opening Table 1
On the Phenix home page, navigate to the project you for which you wish to generate a Table 1.
This will give you many values of your structure, including the Rfree, Rwork, correlation
coefficient, resolution, and percent completeness. Under the ‘Utilities’ tab on the Phenix
homepage, click ‘Generate “Table 1” for journal.’ Under the ‘Options’ tab that pop up, make
sure that ‘CSV’ is checked. A .csv file is compatible with Excel and will allow you to view it
there. In the ‘Structure data’ tab, designate the .pdb file, .mtz file, and unmerged data.
Step 1: Unmerge Data
To get an unmerged file of your data, you will need to run HKL2000 again on that project. Run
HKL2000 normally as you did before. Then, after you have scaled your sets (you may want to
put these output files into a different folder or name them something different to tell the
difference between your previous ones), go to the ‘Macros’ tab and input the follow macro to
both the ‘During Integration’ and ‘During Scaling’ lines: no merge original index You will
have to click ‘Add Macro’ when done.
Then, delete the rejection file and re-scale your sets. You will get a message that says something
along the lines of ‘unable to read file… may be because of no merge.’ This is fine since you did
ask HKL to not merge.
Step 2: Using Multiple Data Sets
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If you had more than one data set for this project, you will again have to run HKL twice and get
two unmerged output files. Like before, you will merge them using CCP4.
Open CCP4 and open ‘Symmetry, Scale, Merge (Aimless).’ Then, in the Aimless window, make
sure that ‘Option to skip scaling and just merge,’ ‘Customize output options,’ ‘Assign to the
same dataset as the previous file,’ and ‘Cell Dimensions’ are checked. Change ‘Input reflection
file type’ to ‘Scalepack file.’ Change ‘MTZ Output’ to ‘scaled, unmerged & no outliers’ and
change ‘Scalepack Output’ to ‘No output.’ You should have SCA #1 and SCA #2 available for
input. Choose your files, set your cell dimensions, and click ‘Run’ and ‘Run Now.’
This will be the ‘Unmerged data’ file in Phenix for generating the Table 1.
Step 3: .pdb and .mtz for Table 1
Your .pdb file will be that of your best refinement. The .mtz file will be the data.mtz file that you
used to refine your .pdb file against. If you can’t remember which ones these were, you can view
it by doing the following. Under the ‘Job history’ tab of Phenix home, double click your best
refinement. Under ‘Configure,’ you can see the files that Phenix used to refine.
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Appendix C: Tutorial on How to Make Publication Quality Images in PyMOL
Command
Color grey50, map
Set mesh_width, 0.5
Bg_color white
Set ray_trace_fog, 0
Set depth_cue, 0
Ray
Ray 1024, 1024

Description
Colors the electron density map grey
Sets the width of the electron density map
mesh
Sets the background color to white
Turns off fog
Turns off depth cues
Produces a rayed image
Produces a rayed image of size 1024x1024
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